

**Experiment Number:** 10034 - 04  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
Bisphenol A  
**CAS Number:** 80-05-7

**Date Report Requested:** 08/16/2017  
**Time Report Requested:** 10:21:03  
**First Dose M/F:** 09/25/12 / 09/25/12  
**Lab:** NCTR

**NTP Study Number:** C10034  
**Lock Date:** 08/16/2017  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.3\_002  
**PWG Approval Date:** 09/29/2017

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR)  
RATS MALE

F1 Veh. Ctrl M

F1 2.5 BPA M

F1 25.0 BPA M

F1 250.0BPA M

F1 2500.BPA M

F1 25000BPA M

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>50</b>	<b>48</b>	<b>48</b>	<b>50</b>	<b>50</b>	<b>46</b>
<b>Early Deaths</b>						
<b>Moribund Sacrifice</b>	<b>20</b>	<b>13</b>	<b>21</b>	<b>17</b>	<b>18</b>	<b>23</b>
<b>Natural Death</b>	<b>10</b>	<b>13</b>	<b>3</b>	<b>11</b>	<b>7</b>	<b>8</b>
<b>Survivors</b>						
<b>Moribund Sacrifice</b>	<b>4</b>	<b>3</b>	<b>6</b>	<b>4</b>	<b>6</b>	<b>4</b>
<b>Natural Death</b>	<b>1</b>	<b>3</b>	<b>1</b>	<b>4</b>	<b>3</b>	
<b>Terminal Sacrifice</b>	<b>15</b>	<b>16</b>	<b>17</b>	<b>14</b>	<b>16</b>	<b>11</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>48</b>	<b>48</b>	<b>50</b>	<b>50</b>	<b>46</b>

ALIMENTARY SYSTEM

Esophagus	(35)	(32)	(31)	(36)	(34)	(35)
Intestine Large, Cecum	(0)	(0)	(0)	(0)	(0)	(0)
Adenoma						
Lymphoma Malignant						
Intestine Large, Colon	(29)	(22)	(31)	(30)	(27)	(30)
Adenocarcinoma	1 (3%)		1 (3%)			
Adenoma					1 (4%)	
Leukemia Granulocytic	1 (3%)					
Lymphoma Malignant				1 (3%)	2 (7%)	
Intestine Large, Rectum	(0)	(0)	(0)	(0)	(0)	(2)
Leiomyosarcoma						1 (50%)
Intestine Small, Duodenum	(0)	(0)	(0)	(0)	(1)	(0)
Adenocarcinoma					1 (100%)	
Adenoma						
Intestine Small, Ileum	(26)	(17)	(27)	(24)	(25)	(28)
Leukemia Granulocytic	1 (4%)					
Lymphoma Malignant					1 (4%)	1 (4%)
Intestine Small, Jejunum	(0)	(0)	(1)	(0)	(1)	(1)
Adenocarcinoma					1 (100%)	1 (100%)
Adenoma						
Liver	(50)	(47)	(48)	(50)	(50)	(45)
Fibrosarcoma, Metastatic, Skin				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A  
CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Hemangiosarcoma		1 (2%)		1 (2%)	1 (2%)	
Hepatocellular Adenoma	1 (2%)			2 (4%)	1 (2%)	
Hepatocellular Adenoma, Multiple			1 (2%)		1 (2%)	
Hepatocellular Carcinoma				2 (4%)	1 (2%)	3 (7%)
Histiocytic Sarcoma	1 (2%)					2 (4%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lipoma				1 (2%)		
Lymphoma Malignant	2 (4%)	1 (2%)	3 (6%)	3 (6%)	3 (6%)	2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Mesentery	(1)	(0)	(4)	(1)	(1)	(4)
Leukemia Mononuclear						
Liposarcoma, Metastatic, Kidney						
Lymphoma Malignant						
Oral Mucosa	(1)	(0)	(1)	(0)	(1)	(0)
Fibrosarcoma					1 (100%)	
Squamous Cell Carcinoma	1 (100%)		1 (100%)			
Squamous Cell Papilloma						
Pancreas	(50)	(46)	(48)	(49)	(48)	(44)
Fibroma					1 (2%)	
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)					
Liposarcoma, Metastatic, Kidney						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)	2 (4%)	3 (6%)	2 (5%)
Sarcoma, Metastatic, Spleen						
Acinar Cell, Adenoma	1 (2%)			1 (2%)		
Salivary Glands	(0)	(0)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(36)	(31)	(33)	(36)	(32)	(34)
Lymphoma Malignant						
Squamous Cell Carcinoma						
Squamous Cell Papilloma	2 (6%)					
Stomach, Glandular	(34)	(30)	(33)	(32)	(33)	(33)
Adenoma						
Leukemia Mononuclear						
Lymphoma Malignant					1 (3%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Schwannoma Malignant						
Squamous Cell Papilloma			1 (3%)			
Tongue	(0)	(1)	(0)	(0)	(0)	(1)
Squamous Cell Papilloma						1 (100%)
<b>CARDIOVASCULAR SYSTEM</b>						
Blood Vessel	(50)	(48)	(48)	(50)	(50)	(46)
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant						
Mesothelioma Malignant						
Heart	(50)	(48)	(48)	(50)	(50)	(46)
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)		2 (4%)	3 (6%)	2 (4%)
Mesothelioma Malignant						
Schwannoma Malignant						
Atrium, Mesothelioma Malignant						
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(50)	(48)	(48)	(50)	(48)	(45)
Adenoma	1 (2%)			1 (2%)	2 (4%)	
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Adrenal Medulla	(50)	(48)	(47)	(50)	(50)	(45)
Leukemia Granulocytic						
Lymphoma Malignant				1 (2%)		
Pheochromocytoma Benign	3 (6%)	3 (6%)	2 (4%)	3 (6%)	2 (4%)	
Pheochromocytoma Malignant	1 (2%)	1 (2%)	1 (2%)			1 (2%)
Bilateral, Pheochromocytoma Benign						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Bilateral, Pheochromocytoma Malignant	1 (2%)				1 (2%)	
Islets, Pancreatic	(50)	(46)	(48)	(48)	(49)	(45)
Adenoma	2 (4%)	3 (7%)	7 (15%)	1 (2%)	4 (8%)	5 (11%)
Carcinoma		3 (7%)				
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						
Lymphoma Malignant				1 (2%)	1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Parathyroid Gland	(49)	(46)	(47)	(50)	(50)	(46)
Adenoma						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant				1 (2%)		
Pituitary Gland	(48)	(48)	(48)	(50)	(50)	(45)
Craniopharyngioma						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant	2 (4%)	1 (2%)	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Pars Distalis, Adenoma	21 (44%)	25 (52%)	23 (48%)	21 (42%)	21 (42%)	17 (38%)
Pars Distalis, Carcinoma					1 (2%)	
Pars Intermedia, Adenoma		1 (2%)	1 (2%)			
Thyroid Gland	(46)	(40)	(47)	(44)	(44)	(44)
Leukemia Granulocytic						
Lymphoma Malignant	1 (2%)			1 (2%)	1 (2%)	1 (2%)
C-cell, Adenoma					2 (5%)	
C-cell, Carcinoma		1 (3%)		1 (2%)		
Follicular Cell, Adenoma						
Follicular Cell, Carcinoma		1 (3%)	1 (2%)			
<b>GENERAL BODY SYSTEM</b>						
Peritoneum	(0)	(0)	(0)	(0)	(0)	(1)
Paraganglioma						1 (100%)
Tissue NOS	(2)	(0)	(0)	(0)	(1)	(1)
Leukemia Mononuclear	1 (50%)					
Mesothelioma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Sarcoma	1 (50%)					
Sarcoma, Metastatic, Uncertain Primary Site					1 (100%)	
<b>GENITAL SYSTEM</b>						
Bulbourethral Gland	(1)	(0)	(0)	(0)	(0)	(0)
Coagulating Gland	(47)	(46)	(47)	(49)	(46)	(45)
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						
Leukemia Mononuclear			1 (2%)			
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Ductus Deferens	(0)	(0)	(1)	(0)	(0)	(0)
Epididymis	(49)	(48)	(48)	(50)	(50)	(46)
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						
Lymphoma Malignant	2 (4%)	1 (2%)		1 (2%)	1 (2%)	1 (2%)
Mesothelioma Malignant				2 (4%)		1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Fat Pad, Epididymal	(2)	(2)	(0)	(1)	(3)	(1)
Leukemia Granulocytic					1 (33%)	
Lipoma				1 (100%)		
Sarcoma, Metastatic, Uncertain Primary Site					1 (33%)	
Preputial Gland	(15)	(15)	(15)	(13)	(16)	(9)
Adenoma						
Carcinoma	3 (20%)	2 (13%)	5 (33%)	5 (38%)	8 (50%)	3 (33%)
Carcinosarcoma						
Lymphoma Malignant						
Squamous Cell Carcinoma						
Squamous Cell Papilloma	1 (7%)	1 (7%)		1 (8%)	1 (6%)	
Bilateral, Carcinoma	1 (7%)					
Prostate, Dorsal/lateral Lobe	(50)	(48)	(48)	(50)	(50)	(46)
Adenocarcinoma						
Adenoma						1 (2%)
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Leukemia Mononuclear			1 (2%)			
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)	1 (2%)	3 (6%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Prostate, Ventral Lobe	(50)	(48)	(48)	(49)	(49)	(46)
Adenoma	6 (12%)	5 (10%)	2 (4%)	4 (8%)	2 (4%)	3 (7%)
Adenoma, Multiple		2 (4%)				3 (7%)
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						
Leukemia Mononuclear			1 (2%)			
Lymphoma Malignant		1 (2%)	1 (2%)	1 (2%)		1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Seminal Vesicle	(44)	(42)	(45)	(41)	(44)	(43)
Adenoma				1 (2%)		
Carcinosarcoma						
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic						
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Testes	(49)	(48)	(48)	(50)	(50)	(46)
Histiocytic Sarcoma	1 (2%)					
Mesothelioma Malignant				2 (4%)		1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Seminoma Benign						
Seminoma Malignant		1 (2%)				
Interstitial Cell, Adenoma						
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(48)	(48)	(48)	(49)	(50)	(45)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant	2 (4%)	1 (2%)	3 (6%)	3 (6%)	3 (6%)	2 (4%)
Osteosarcoma, Metastatic, Bone, Femur						
Lymph Node	(15)	(9)	(13)	(15)	(16)	(11)
Axillary, Leukemia Granulocytic						
Axillary, Lymphoma Malignant		1 (11%)		1 (7%)	1 (6%)	1 (9%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Brachial, Leukemia Granulocytic						
Brachial, Lymphoma Malignant			1 (8%)		1 (6%)	
Cervical, Leukemia Granulocytic						
Cervical, Lymphoma Malignant	1 (7%)		1 (8%)		1 (6%)	1 (9%)
Inguinal, Leukemia Granulocytic						
Inguinal, Lymphoma Malignant					1 (6%)	1 (9%)
Lumbar, Carcinoma, Metastatic, Preputial Gland						
Lumbar, Leukemia Granulocytic						
Lumbar, Lymphoma Malignant	1 (7%)	1 (11%)	2 (15%)	2 (13%)	1 (6%)	1 (9%)
Lumbar, Sarcoma, Metastatic, Skin					1 (6%)	
Mediastinal, Histiocytic Sarcoma	1 (7%)					1 (9%)
Mediastinal, Leukemia Granulocytic	1 (7%)					
Mediastinal, Lymphoma Malignant	1 (7%)	1 (11%)	1 (8%)	2 (13%)	2 (13%)	1 (9%)
Pancreatic, Leukemia Granulocytic	1 (7%)					
Pancreatic, Lymphoma Malignant	2 (13%)	1 (11%)	1 (8%)	1 (7%)	2 (13%)	2 (18%)
Popliteal, Lymphoma Malignant					1 (6%)	1 (9%)
Renal, Hemangioma					1 (6%)	
Renal, Leukemia Granulocytic	1 (7%)					
Renal, Leukemia Mononuclear						
Renal, Lymphoma Malignant	2 (13%)		1 (8%)		2 (13%)	2 (18%)
Lymph Node, Mandibular	(7)	(10)	(9)	(8)	(9)	(4)
Leukemia Granulocytic	1 (14%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (29%)	1 (10%)	1 (11%)	2 (25%)	2 (22%)	2 (50%)
Squamous Cell Carcinoma, Metastatic, Skin						
Lymph Node, Mesenteric	(0)	(1)	(1)	(1)	(2)	(3)
Leukemia Granulocytic						
Lymphoma Malignant		1 (100%)		1 (100%)	1 (50%)	2 (67%)
Spleen	(49)	(47)	(48)	(47)	(49)	(45)
Hemangiosarcoma					1 (2%)	
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)		1 (2%)			
Liposarcoma						
Lymphoma Malignant	2 (4%)	1 (2%)	3 (6%)	3 (6%)	3 (6%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Sarcoma		2 (4%)	1 (2%)			
Sarcoma, Metastatic, Uncertain Primary Site					1 (2%)	
Thymus	(50)	(46)	(46)	(49)	(49)	(43)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear			1 (2%)			
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)	2 (4%)	2 (4%)	2 (5%)
Mesothelioma Malignant						
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(50)	(48)	(48)	(50)	(50)	(45)
Adenocarcinoma						
Adenocarcinoma, Multiple	1 (2%)					
Adenoma						
Fibroadenoma		1 (2%)	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Fibroadenoma, Multiple		1 (2%)			1 (2%)	
Fibroma	2 (4%)				2 (4%)	
Fibroma, Multiple						1 (2%)
Histiocytic Sarcoma						
Leukemia Granulocytic						
Lipoma						
Lymphoma Malignant		1 (2%)			1 (2%)	
Skin	(12)	(16)	(14)	(14)	(19)	(17)
Basal Cell Adenoma				1 (7%)		1 (6%)
Basal Cell Carcinoma						
Fibroma	1 (8%)					
Keratoacanthoma						
Pilomatrixoma	1 (8%)					
Squamous Cell Carcinoma		2 (13%)	1 (7%)			
Squamous Cell Papilloma		2 (13%)	1 (7%)	2 (14%)	2 (11%)	
Sebaceous Gland, Adenoma						1 (6%)
Subcutaneous Tissue, Fibroma		1 (6%)	1 (7%)	1 (7%)	1 (5%)	1 (6%)
Subcutaneous Tissue, Fibrosarcoma			2 (14%)	1 (7%)		2 (12%)
Subcutaneous Tissue, Histiocytic Sarcoma						1 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Subcutaneous Tissue, Histiocytic Sarcoma, Metastatic, Liver						1 (6%)
Subcutaneous Tissue, Lipoma		1 (6%)	1 (7%)	1 (7%)	1 (5%)	
Subcutaneous Tissue, Myxosarcoma			1 (7%)			
Subcutaneous Tissue, Sarcoma		1 (6%)			1 (5%)	
Subcutaneous Tissue, Schwannoma Malignant						
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(1)	(0)	(1)	(2)	(2)	(1)
Cranium, Lymphoma Malignant						
Cranium, Osteosarcoma					1 (50%)	
Mandible, Squamous Cell Carcinoma, Deep Invasion						
Rib, Osteosarcoma	1 (100%)					1 (100%)
Tibia, Osteosarcoma				1 (50%)		
Vertebra, Chordoma				1 (50%)		
Vertebra, Lymphoma Malignant						
Bone, Femur	(50)	(48)	(48)	(50)	(50)	(46)
Osteosarcoma						
Skeletal Muscle	(2)	(0)	(3)	(1)	(1)	(1)
Lymphoma Malignant						
Mesothelioma Malignant						
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(49)	(48)	(48)	(49)	(49)	(46)
Carcinoma, Deep Invasion					1 (2%)	
Granular Cell Tumor Benign		1 (2%)				
Granular Cell Tumor Malignant						
Leukemia Granulocytic						
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant			1 (2%)		2 (4%)	
Brain, Cerebellum	(50)	(48)	(48)	(49)	(49)	(46)
Granular Cell Tumor Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Leukemia Granulocytic						
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant					1 (2%)	
Brain, Cerebrum	(50)	(48)	(48)	(49)	(49)	(46)
Granular Cell Tumor Benign				4 (8%)	1 (2%)	
Granular Cell Tumor Malignant	1 (2%)	1 (2%)				
Leukemia Granulocytic						
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant			2 (4%)	1 (2%)		1 (2%)
Meningioma Benign						
Oligodendroglioma Malignant						
Sarcoma						
Nerve Trigeminal	(11)	(6)	(5)	(9)	(14)	(8)
Lymphoma Malignant						
Peripheral Nerve, Sciatic	(11)	(6)	(5)	(9)	(14)	(8)
Histiocytic Sarcoma	1 (9%)					
Peripheral Nerve, Tibial	(11)	(6)	(5)	(9)	(14)	(8)
Histiocytic Sarcoma	1 (9%)					
Spinal Cord, Cervical	(11)	(6)	(5)	(8)	(14)	(8)
Spinal Cord, Lumbar	(11)	(6)	(5)	(8)	(14)	(8)
Lymphoma Malignant						
Spinal Cord, Thoracic	(11)	(6)	(5)	(8)	(14)	(8)
<b>RESPIRATORY SYSTEM</b>						
Lung	(38)	(39)	(34)	(38)	(35)	(36)
Alveolar/Bronchiolar Adenoma	1 (3%)					
Alveolar/Bronchiolar Carcinoma		1 (3%)				
Carcinoma, Metastatic, Zymbal'S Gland						
Chordoma, Metastatic, Bone				1 (3%)		
Histiocytic Sarcoma	1 (3%)					1 (3%)
Leukemia Granulocytic	1 (3%)				1 (3%)	
Leukemia Mononuclear	1 (3%)		1 (3%)			
Lymphoma Malignant	2 (5%)	1 (3%)	2 (6%)	2 (5%)	3 (9%)	2 (6%)
Mesothelioma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Neural Crest Tumor, Malignant, Metastatic, Ear						
Osteosarcoma, Metastatic, Bone, Femur						
Sarcoma						
Sarcoma, Metastatic, Tissue Nos						
Sarcoma, Metastatic, Uncertain Primary Site					1 (3%)	
Nose	(33)	(32)	(31)	(34)	(32)	(35)
Adenoma						
Leukemia Granulocytic	1 (3%)				1 (3%)	
Leukemia Mononuclear						
Lymphoma Malignant	2 (6%)	1 (3%)	3 (10%)	1 (3%)	2 (6%)	2 (6%)
Sarcoma, Metastatic, Brain, Cerebrum						
Squamous Cell Carcinoma			1 (3%)		2 (6%)	
Trachea	(31)	(23)	(30)	(27)	(32)	(33)
Lymphoma Malignant						
<b>SPECIAL SENSES SYSTEM</b>						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Neural Crest Tumor, Benign						
Neural Crest Tumor, Malignant						
Eye	(4)	(1)	(0)	(1)	(1)	(1)
Lymphoma Malignant						
Lacrimal Gland	(0)	(0)	(0)	(0)	(0)	(0)
Zymbal's Gland	(2)	(0)	(3)	(0)	(1)	(1)
Adenoma			2 (67%)			1 (100%)
Carcinoma	1 (50%)		1 (33%)			
<b>URINARY SYSTEM</b>						
Kidney	(50)	(48)	(48)	(50)	(50)	(45)
Adenoma, Tubular						
Histiocytic Sarcoma	1 (2%)					
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lipoma	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
Liposarcoma						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)	3 (6%)	3 (6%)	2 (4%)
Mesenchymal Tumor Malignant						
Oncocytoma Benign			1 (2%)			
Sarcoma, Metastatic, Spleen		1 (2%)				
Urinary Bladder	(4)	(1)	(3)	(5)	(4)	(3)
Transitional Epithelium, Carcinoma				1 (20%)		
Transitional Epithelium, Papilloma						1 (33%)
SYSTEMIC LESIONS						
Multiple Organ	*(50)	*(48)	*(48)	*(50)	*(50)	*(46)
Histiocytic Sarcoma	1 (2%)					2 (4%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Leukemia Mononuclear	1 (2%)		1 (2%)			
Lymphoma Malignant	2 (4%)	1 (2%)	3 (6%)	3 (6%)	3 (6%)	3 (7%)
Mesothelioma Malignant				2 (4%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
------------------------------------	---------------	---------------	------------------	-----------------	------------------	------------------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>26</b>	<b>26</b>	<b>50</b>	<b>48</b>	<b>48</b>	<b>50</b>
<b>Early Deaths</b>						
<b>Moribund Sacrifice</b>	<b>12</b>	<b>8</b>	<b>16</b>	<b>17</b>	<b>19</b>	<b>25</b>
<b>Natural Death</b>	<b>3</b>	<b>3</b>	<b>10</b>	<b>9</b>	<b>4</b>	<b>5</b>
<b>Survivors</b>						
<b>Moribund Sacrifice</b>	<b>2</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>5</b>	<b>4</b>
<b>Natural Death</b>		<b>1</b>	<b>3</b>	<b>3</b>	<b>4</b>	<b>3</b>
<b>Terminal Sacrifice</b>	<b>9</b>	<b>12</b>	<b>17</b>	<b>16</b>	<b>16</b>	<b>13</b>
<b>Animals Examined Microscopically</b>	<b>26</b>	<b>26</b>	<b>50</b>	<b>48</b>	<b>48</b>	<b>50</b>

ALIMENTARY SYSTEM

Esophagus	(17)	(14)	(32)	(32)	(32)	(37)
Intestine Large, Cecum	(0)	(0)	(1)	(1)	(1)	(0)
Adenoma					1 (100%)	
Lymphoma Malignant						
Intestine Large, Colon	(15)	(11)	(21)	(26)	(24)	(33)
Adenocarcinoma	1 (7%)		1 (5%)			
Adenoma			1 (5%)			
Leukemia Granulocytic						
Lymphoma Malignant	1 (7%)					1 (3%)
Intestine Large, Rectum	(0)	(0)	(0)	(0)	(0)	(0)
Leiomyosarcoma						
Intestine Small, Duodenum	(0)	(0)	(0)	(1)	(0)	(0)
Adenocarcinoma				1 (100%)		
Adenoma						
Intestine Small, Ileum	(14)	(10)	(20)	(22)	(24)	(31)
Leukemia Granulocytic						
Lymphoma Malignant	1 (7%)					
Intestine Small, Jejunum	(1)	(0)	(1)	(3)	(1)	(1)
Adenocarcinoma			1 (100%)	2 (67%)		1 (100%)
Adenoma				1 (33%)		
Liver	(26)	(25)	(50)	(48)	(48)	(50)
Fibrosarcoma, Metastatic, Skin						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Hemangiosarcoma						
Hepatocellular Adenoma		1 (4%)	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Hepatocellular Adenoma, Multiple						
Hepatocellular Carcinoma		1 (4%)		1 (2%)	1 (2%)	2 (4%)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		2 (4%)	
Lipoma						
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)
Sarcoma, Metastatic, Uncertain Primary Site						
Mesentery	(1)	(1)	(1)	(2)	(3)	(1)
Leukemia Mononuclear					1 (33%)	
Liposarcoma, Metastatic, Kidney				1 (50%)		
Lymphoma Malignant						1 (100%)
Oral Mucosa	(0)	(0)	(1)	(0)	(1)	(0)
Fibrosarcoma						
Squamous Cell Carcinoma					1 (100%)	
Squamous Cell Papilloma			1 (100%)			
Pancreas	(26)	(25)	(47)	(46)	(47)	(49)
Fibroma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear					1 (2%)	
Liposarcoma, Metastatic, Kidney				1 (2%)		
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)
Sarcoma, Metastatic, Spleen	1 (4%)					
Acinar Cell, Adenoma	1 (4%)	1 (4%)	1 (2%)	1 (2%)		
Salivary Glands	(0)	(0)	(0)	(0)	(0)	(1)
Stomach, Forestomach	(17)	(15)	(31)	(33)	(34)	(37)
Lymphoma Malignant	1 (6%)					1 (3%)
Squamous Cell Carcinoma	1 (6%)					
Squamous Cell Papilloma			1 (3%)	1 (3%)		
Stomach, Glandular	(16)	(12)	(30)	(29)	(27)	(35)
Adenoma				1 (3%)		
Leukemia Mononuclear					1 (4%)	
Lymphoma Malignant						2 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A  
CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Schwannoma Malignant						1 (3%)
Squamous Cell Papilloma						
Tongue	(0)	(0)	(0)	(0)	(0)	(1)
Squamous Cell Papilloma						
<b>CARDIOVASCULAR SYSTEM</b>						
Blood Vessel	(26)	(26)	(50)	(48)	(48)	(50)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Lymphoma Malignant	1 (4%)					
Mesothelioma Malignant				1 (2%)		
Heart	(26)	(26)	(50)	(48)	(48)	(50)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		1 (2%)	
Lymphoma Malignant	1 (4%)	1 (4%)	1 (2%)		1 (2%)	2 (4%)
Mesothelioma Malignant				1 (2%)		
Schwannoma Malignant				1 (2%)		
Atrium, Mesothelioma Malignant						
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(26)	(26)	(47)	(47)	(48)	(49)
Adenoma	1 (4%)			2 (4%)	1 (2%)	
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		1 (2%)	
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Adrenal Medulla	(26)	(26)	(47)	(46)	(48)	(49)
Leukemia Granulocytic					1 (2%)	
Lymphoma Malignant						
Pheochromocytoma Benign	1 (4%)		4 (9%)	2 (4%)	5 (10%)	5 (10%)
Pheochromocytoma Malignant			1 (2%)	1 (2%)		
Bilateral, Pheochromocytoma Benign	1 (4%)	1 (4%)		1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Bilateral, Pheochromocytoma Malignant						
Islets, Pancreatic	(26)	(26)	(48)	(47)	(48)	(48)
Adenoma			4 (8%)	4 (9%)	2 (4%)	4 (8%)
Carcinoma				1 (2%)	2 (4%)	
Histiocytic Sarcoma						
Leukemia Granulocytic					1 (2%)	
Lymphoma Malignant						
Sarcoma, Metastatic, Uncertain Primary Site						
Parathyroid Gland	(25)	(25)	(49)	(46)	(46)	(49)
Adenoma		1 (4%)	1 (2%)			
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (4%)					
Pituitary Gland	(26)	(26)	(46)	(48)	(48)	(49)
Craniopharyngioma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		1 (2%)	
Lymphoma Malignant	2 (8%)	1 (4%)			1 (2%)	2 (4%)
Pars Distalis, Adenoma	12 (46%)	6 (23%)	29 (63%)	22 (46%)	19 (40%)	19 (39%)
Pars Distalis, Carcinoma					1 (2%)	
Pars Intermedia, Adenoma				1 (2%)		
Thyroid Gland	(25)	(25)	(43)	(45)	(44)	(45)
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant	1 (4%)	1 (4%)				2 (4%)
C-cell, Adenoma				1 (2%)		
C-cell, Carcinoma			1 (2%)			
Follicular Cell, Adenoma	1 (4%)			1 (2%)		
Follicular Cell, Carcinoma						
<b>GENERAL BODY SYSTEM</b>						
Peritoneum	(0)	(0)	(0)	(0)	(0)	(0)
Paraganglioma						
Tissue NOS	(0)	(1)	(0)	(1)	(0)	(1)
Leukemia Mononuclear						
Mesothelioma Malignant				1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Sarcoma						1 (100%)
Sarcoma, Metastatic, Uncertain Primary Site						
<b>GENITAL SYSTEM</b>						
Bulbourethral Gland	(0)	(0)	(0)	(1)	(0)	(0)
Coagulating Gland	(26)	(25)	(45)	(45)	(44)	(50)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Leukemia Mononuclear						
Sarcoma, Metastatic, Uncertain Primary Site						
Ductus Deferens	(0)	(1)	(0)	(0)	(0)	(0)
Epididymis	(26)	(26)	(49)	(48)	(48)	(50)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Lymphoma Malignant		1 (4%)				3 (6%)
Mesothelioma Malignant						
Sarcoma, Metastatic, Uncertain Primary Site						
Fat Pad, Epididymal	(0)	(0)	(0)	(0)	(0)	(4)
Leukemia Granulocytic						
Lipoma						
Sarcoma, Metastatic, Uncertain Primary Site						
Preputial Gland	(4)	(6)	(14)	(16)	(17)	(19)
Adenoma		1 (17%)			1 (6%)	
Carcinoma	4 (100%)	1 (17%)	6 (43%)	3 (19%)	4 (24%)	6 (32%)
Carcinosarcoma						
Lymphoma Malignant						
Squamous Cell Carcinoma						
Squamous Cell Papilloma				1 (6%)		1 (5%)
Bilateral, Carcinoma				2 (13%)		
Prostate, Dorsal/lateral Lobe	(26)	(25)	(46)	(48)	(48)	(50)
Adenocarcinoma					1 (2%)	
Adenoma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Leukemia Mononuclear					1 (2%)	
Lymphoma Malignant	1 (4%)	1 (4%)				3 (6%)
Sarcoma, Metastatic, Uncertain Primary Site						
Prostate, Ventral Lobe	(26)	(26)	(48)	(47)	(47)	(50)
Adenoma	1 (4%)	2 (8%)	3 (6%)	2 (4%)	3 (6%)	1 (2%)
Adenoma, Multiple	1 (4%)		1 (2%)	2 (4%)	1 (2%)	1 (2%)
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Leukemia Mononuclear						
Lymphoma Malignant	1 (4%)	1 (4%)				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Seminal Vesicle	(25)	(23)	(39)	(43)	(41)	(47)
Adenoma						
Carcinosarcoma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site						
Testes	(26)	(26)	(49)	(48)	(48)	(50)
Histiocytic Sarcoma						
Mesothelioma Malignant						
Sarcoma, Metastatic, Uncertain Primary Site						
Seminoma Benign				1 (2%)		
Seminoma Malignant						
Interstitial Cell, Adenoma	1 (4%)		1 (2%)		1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(26)	(25)	(47)	(47)	(46)	(50)
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		2 (4%)	
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)			3 (6%)
Osteosarcoma, Metastatic, Bone, Femur						
Lymph Node	(7)	(6)	(16)	(17)	(15)	(15)
Axillary, Leukemia Granulocytic					1 (7%)	
Axillary, Lymphoma Malignant		1 (17%)				2 (13%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Brachial, Leukemia Granulocytic				1 (6%)		
Brachial, Lymphoma Malignant		1 (17%)				1 (7%)
Cervical, Leukemia Granulocytic				1 (6%)		
Cervical, Lymphoma Malignant		1 (17%)				1 (7%)
Inguinal, Leukemia Granulocytic				1 (6%)		
Inguinal, Lymphoma Malignant						1 (7%)
Lumbar, Carcinoma, Metastatic, Preputial Gland					1 (7%)	
Lumbar, Leukemia Granulocytic				1 (6%)	1 (7%)	
Lumbar, Lymphoma Malignant	2 (29%)	1 (17%)	1 (6%)		1 (7%)	2 (13%)
Lumbar, Sarcoma, Metastatic, Skin						
Mediastinal, Histiocytic Sarcoma						
Mediastinal, Leukemia Granulocytic				1 (6%)	1 (7%)	
Mediastinal, Lymphoma Malignant	1 (14%)	1 (17%)	1 (6%)		1 (7%)	2 (13%)
Pancreatic, Leukemia Granulocytic					1 (7%)	
Pancreatic, Lymphoma Malignant	2 (29%)	1 (17%)	1 (6%)		1 (7%)	3 (20%)
Popliteal, Lymphoma Malignant						1 (7%)
Renal, Hemangioma						
Renal, Leukemia Granulocytic				1 (6%)	1 (7%)	
Renal, Leukemia Mononuclear			1 (6%)			
Renal, Lymphoma Malignant	2 (29%)	1 (17%)	1 (6%)			2 (13%)
Lymph Node, Mandibular	(6)	(7)	(8)	(8)	(14)	(9)
Leukemia Granulocytic				1 (13%)	1 (7%)	
Leukemia Mononuclear			1 (13%)		1 (7%)	
Lymphoma Malignant	2 (33%)	1 (14%)	1 (13%)			3 (33%)
Squamous Cell Carcinoma, Metastatic, Skin			1 (13%)		1 (7%)	
Lymph Node, Mesenteric	(0)	(1)	(1)	(2)	(1)	(2)
Leukemia Granulocytic				1 (50%)	1 (100%)	
Lymphoma Malignant		1 (100%)	1 (100%)			1 (50%)
Spleen	(26)	(25)	(47)	(47)	(47)	(49)
Hemangiosarcoma						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		2 (4%)	
Liposarcoma				1 (2%)		
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Sarcoma	2 (8%)			1 (2%)	1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site						
Thymus	(24)	(25)	(48)	(48)	(46)	(47)
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear					1 (2%)	
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)
Mesothelioma Malignant				1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(25)	(25)	(49)	(48)	(47)	(50)
Adenocarcinoma		1 (4%)				
Adenocarcinoma, Multiple						
Adenoma						
Fibroadenoma			1 (2%)	1 (2%)	1 (2%)	1 (2%)
Fibroadenoma, Multiple						
Fibroma		2 (8%)	1 (2%)			1 (2%)
Fibroma, Multiple						
Histiocytic Sarcoma		1 (4%)				
Leukemia Granulocytic				1 (2%)	1 (2%)	
Lipoma		1 (4%)				
Lymphoma Malignant		1 (4%)				
Skin	(6)	(7)	(21)	(18)	(24)	(15)
Basal Cell Adenoma		1 (14%)	1 (5%)	1 (6%)	1 (4%)	
Basal Cell Carcinoma		1 (14%)				1 (7%)
Fibroma			1 (5%)			
Keratoacanthoma					1 (4%)	
Pilomatrixoma						
Squamous Cell Carcinoma			2 (10%)		1 (4%)	
Squamous Cell Papilloma		1 (14%)	3 (14%)		4 (17%)	1 (7%)
Sebaceous Gland, Adenoma				1 (6%)		
Subcutaneous Tissue, Fibroma			1 (5%)	5 (28%)	2 (8%)	
Subcutaneous Tissue, Fibrosarcoma			1 (5%)			1 (7%)
Subcutaneous Tissue, Histiocytic Sarcoma		1 (14%)				1 (7%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Subcutaneous Tissue, Histiocytic Sarcoma, Metastatic, Liver						
Subcutaneous Tissue, Lipoma		2 (29%)	2 (10%)		2 (8%)	
Subcutaneous Tissue, Myxosarcoma						
Subcutaneous Tissue, Sarcoma						
Subcutaneous Tissue, Schwannoma Malignant			1 (5%)		1 (4%)	2 (13%)
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(1)	(1)	(3)	(0)	(1)	(1)
Cranium, Lymphoma Malignant	1 (100%)					
Cranium, Osteosarcoma						
Mandible, Squamous Cell Carcinoma, Deep Invasion			1 (33%)			
Rib, Osteosarcoma						
Tibia, Osteosarcoma						
Vertebra, Chordoma						
Vertebra, Lymphoma Malignant	1 (100%)					
Bone, Femur	(26)	(26)	(50)	(48)	(48)	(50)
Osteosarcoma						
Skeletal Muscle	(2)	(0)	(1)	(1)	(1)	(2)
Lymphoma Malignant	1 (50%)					
Mesothelioma Malignant				1 (100%)		
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(26)	(26)	(50)	(48)	(47)	(50)
Carcinoma, Deep Invasion					1 (2%)	
Granular Cell Tumor Benign						
Granular Cell Tumor Malignant					1 (2%)	1 (2%)
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear						
Lymphoma Malignant	1 (4%)					
Brain, Cerebellum	(26)	(26)	(49)	(48)	(48)	(50)
Granular Cell Tumor Malignant		1 (4%)	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear					1 (2%)	
Lymphoma Malignant						
Brain, Cerebrum	(26)	(26)	(49)	(48)	(48)	(50)
Granular Cell Tumor Benign				1 (2%)		1 (2%)
Granular Cell Tumor Malignant	1 (4%)				1 (2%)	1 (2%)
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		1 (2%)	
Lymphoma Malignant	1 (4%)	1 (4%)				1 (2%)
Meningioma Benign		1 (4%)				
Oligodendroglioma Malignant						
Sarcoma						
Nerve Trigeminal	(4)	(3)	(2)	(0)	(2)	(6)
Lymphoma Malignant						
Peripheral Nerve, Sciatic	(4)	(3)	(2)	(0)	(2)	(6)
Histiocytic Sarcoma						
Peripheral Nerve, Tibial	(4)	(3)	(2)	(0)	(2)	(6)
Histiocytic Sarcoma						
Spinal Cord, Cervical	(4)	(3)	(2)	(0)	(2)	(6)
Spinal Cord, Lumbar	(4)	(3)	(2)	(0)	(2)	(6)
Lymphoma Malignant						
Spinal Cord, Thoracic	(4)	(3)	(2)	(0)	(2)	(6)

RESPIRATORY SYSTEM

Lung	(19)	(13)	(36)	(33)	(39)	(40)
Alveolar/Bronchiolar Adenoma						
Alveolar/Bronchiolar Carcinoma						
Carcinoma, Metastatic, Zymbal'S Gland	1 (5%)					
Chordoma, Metastatic, Bone						
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (3%)	1 (3%)	
Leukemia Mononuclear			1 (3%)		1 (3%)	
Lymphoma Malignant	2 (11%)	1 (8%)	1 (3%)		1 (3%)	3 (8%)
Mesothelioma Malignant				1 (3%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Neural Crest Tumor, Malignant, Metastatic, Ear						1 (3%)
Osteosarcoma, Metastatic, Bone, Femur						
Sarcoma						
Sarcoma, Metastatic, Tissue Nos						
Sarcoma, Metastatic, Uncertain Primary Site						
Nose	(17)	(12)	(30)	(32)	(31)	(37)
Adenoma						
Leukemia Granulocytic				1 (3%)	1 (3%)	
Leukemia Mononuclear					1 (3%)	
Lymphoma Malignant	2 (12%)	1 (8%)			1 (3%)	3 (8%)
Sarcoma, Metastatic, Brain, Cerebrum						
Squamous Cell Carcinoma					2 (6%)	
Trachea	(17)	(12)	(27)	(26)	(27)	(32)
Lymphoma Malignant		1 (8%)				2 (6%)
<b>SPECIAL SENSES SYSTEM</b>						
Ear	(1)	(0)	(0)	(0)	(0)	(1)
Neural Crest Tumor, Benign	1 (100%)					
Neural Crest Tumor, Malignant						1 (100%)
Eye	(3)	(2)	(2)	(1)	(2)	(1)
Lymphoma Malignant		1 (50%)				
Lacrimal Gland	(0)	(0)	(0)	(1)	(0)	(0)
Zymbal's Gland	(1)	(1)	(0)	(2)	(1)	(1)
Adenoma					1 (100%)	1 (100%)
Carcinoma	1 (100%)	1 (100%)		1 (50%)		
<b>URINARY SYSTEM</b>						
Kidney	(26)	(26)	(50)	(48)	(48)	(50)
Adenoma, Tubular			1 (2%)			
Histiocytic Sarcoma						
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		1 (2%)	
Lipoma				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
Liposarcoma	1 (4%)			2 (4%)	1 (2%)	1 (2%)
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)
Mesenchymal Tumor Malignant				1 (2%)		
Oncocytoma Benign						
Sarcoma, Metastatic, Spleen						
Urinary Bladder	(1)	(0)	(6)	(1)	(4)	(4)
Transitional Epithelium, Carcinoma						
Transitional Epithelium, Papilloma						

---

SYSTEMIC LESIONS

Multiple Organ	*(26)	*(26)	*(50)	*(48)	*(48)	*(50)
Histiocytic Sarcoma		1 (4%)				1 (2%)
Leukemia Granulocytic				1 (2%)	1 (2%)	
Leukemia Mononuclear			1 (2%)		2 (4%)	
Lymphoma Malignant	2 (8%)	1 (4%)	1 (2%)		1 (2%)	3 (6%)
Mesothelioma Malignant				1 (2%)		

---

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR)  
RATS MALE

F1 2500.StDose M

F1 25000StDose M

## Disposition Summary

Animals Initially In Study	50	46
Early Deaths		
Moribund Sacrifice	17	26
Natural Death	7	6
Survivors		
Moribund Sacrifice	10	3
Natural Death	1	2
Terminal Sacrifice	15	9
Animals Examined Microscopically	50	46

## ALIMENTARY SYSTEM

Esophagus	(35)	(36)
Intestine Large, Cecum	(1)	(0)
Adenoma		
Lymphoma Malignant	1 (100%)	
Intestine Large, Colon	(29)	(31)
Adenocarcinoma		
Adenoma		
Leukemia Granulocytic		
Lymphoma Malignant	2 (7%)	2 (6%)
Intestine Large, Rectum	(0)	(0)
Leiomyosarcoma		
Intestine Small, Duodenum	(0)	(1)
Adenocarcinoma		
Adenoma		1 (100%)
Intestine Small, Ileum	(26)	(30)
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	1 (3%)
Intestine Small, Jejunum	(0)	(2)
Adenocarcinoma		
Adenoma		
Liver	(50)	(46)
Fibrosarcoma, Metastatic, Skin		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Hemangiosarcoma		
Hepatocellular Adenoma	1 (2%)	
Hepatocellular Adenoma, Multiple		
Hepatocellular Carcinoma		1 (2%)
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lipoma		
Lymphoma Malignant	2 (4%)	5 (11%)
Sarcoma, Metastatic, Uncertain Primary Site		
Mesentery	(1)	(2)
Leukemia Mononuclear		
Liposarcoma, Metastatic, Kidney		
Lymphoma Malignant		
Oral Mucosa	(1)	(0)
Fibrosarcoma		
Squamous Cell Carcinoma	1 (100%)	
Squamous Cell Papilloma		
Pancreas	(50)	(44)
Fibroma		
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Liposarcoma, Metastatic, Kidney		
Lymphoma Malignant	2 (4%)	2 (5%)
Sarcoma, Metastatic, Spleen		
Acinar Cell, Adenoma	1 (2%)	1 (2%)
Salivary Glands	(0)	(0)
Stomach, Forestomach	(34)	(37)
Lymphoma Malignant		
Squamous Cell Carcinoma		
Squamous Cell Papilloma		
Stomach, Glandular	(33)	(36)
Adenoma		
Leukemia Mononuclear		
Lymphoma Malignant		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
------------------------------------	------------------	------------------

---

Schwannoma Malignant		
Squamous Cell Papilloma		
Tongue	(0)	(0)
Squamous Cell Papilloma		

---

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(46)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Lymphoma Malignant		
Mesothelioma Malignant		
Heart	(50)	(46)
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	3 (7%)
Mesothelioma Malignant		
Schwannoma Malignant	1 (2%)	
Atrium, Mesothelioma Malignant		1 (2%)

---

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(44)
Adenoma	1 (2%)	
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	3 (7%)
Sarcoma, Metastatic, Uncertain Primary Site		
Adrenal Medulla	(50)	(44)
Leukemia Granulocytic		
Lymphoma Malignant		
Pheochromocytoma Benign		4 (9%)
Pheochromocytoma Malignant		
Bilateral, Pheochromocytoma Benign		

---

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Bilateral, Pheochromocytoma Malignant		
Islets, Pancreatic	(50)	(44)
Adenoma	1 (2%)	4 (9%)
Carcinoma	2 (4%)	
Histiocytic Sarcoma		
Leukemia Granulocytic		
Lymphoma Malignant	2 (4%)	
Sarcoma, Metastatic, Uncertain Primary Site		
Parathyroid Gland	(50)	(43)
Adenoma		
Leukemia Granulocytic		
Lymphoma Malignant	2 (4%)	
Pituitary Gland	(50)	(43)
Craniopharyngioma		1 (2%)
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	2 (5%)
Pars Distalis, Adenoma	19 (38%)	17 (40%)
Pars Distalis, Carcinoma		
Pars Intermedia, Adenoma		
Thyroid Gland	(48)	(42)
Leukemia Granulocytic		
Lymphoma Malignant	2 (4%)	1 (2%)
C-cell, Adenoma	1 (2%)	3 (7%)
C-cell, Carcinoma	1 (2%)	
Follicular Cell, Adenoma	1 (2%)	
Follicular Cell, Carcinoma		

---

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)
Paraganglioma		
Tissue NOS	(0)	(1)
Leukemia Mononuclear		
Mesothelioma Malignant		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Sarcoma		1 (100%)
Sarcoma, Metastatic, Uncertain Primary Site		

---

GENITAL SYSTEM

Bulbourethral Gland	(0)	(0)
Coagulating Gland	(48)	(44)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Leukemia Mononuclear		
Sarcoma, Metastatic, Uncertain Primary Site		
Ductus Deferens	(0)	(0)
Epididymis	(50)	(46)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Lymphoma Malignant	2 (4%)	1 (2%)
Mesothelioma Malignant		
Sarcoma, Metastatic, Uncertain Primary Site		
Fat Pad, Epididymal	(0)	(0)
Leukemia Granulocytic		
Lipoma		
Sarcoma, Metastatic, Uncertain Primary Site		
Preputial Gland	(15)	(12)
Adenoma		2 (17%)
Carcinoma	4 (27%)	3 (25%)
Carcinosarcoma		1 (8%)
Lymphoma Malignant	1 (7%)	
Squamous Cell Carcinoma		1 (8%)
Squamous Cell Papilloma		
Bilateral, Carcinoma	1 (7%)	1 (8%)
Prostate, Dorsal/lateral Lobe	(49)	(45)
Adenocarcinoma		
Adenoma		
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
------------------------------------	------------------	------------------

---

Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	4 (9%)
Sarcoma, Metastatic, Uncertain Primary Site		
Prostate, Ventral Lobe	(49)	(45)
Adenoma	2 (4%)	4 (9%)
Adenoma, Multiple	2 (4%)	2 (4%)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant	1 (2%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site		
Seminal Vesicle	(48)	(42)
Adenoma		
Carcinosarcoma	1 (2%)	
Histiocytic Sarcoma		
Leukemia Granulocytic		
Sarcoma, Metastatic, Uncertain Primary Site		
Testes	(49)	(45)
Histiocytic Sarcoma		
Mesothelioma Malignant		
Sarcoma, Metastatic, Uncertain Primary Site		
Seminoma Benign		
Seminoma Malignant	1 (2%)	
Interstitial Cell, Adenoma	1 (2%)	1 (2%)

---

HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(45)
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	5 (11%)
Osteosarcoma, Metastatic, Bone, Femur		1 (2%)
Lymph Node	(27)	(16)
Axillary, Leukemia Granulocytic		
Axillary, Lymphoma Malignant	2 (7%)	2 (13%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Brachial, Leukemia Granulocytic		
Brachial, Lymphoma Malignant	1 (4%)	1 (6%)
Cervical, Leukemia Granulocytic		1 (6%)
Cervical, Lymphoma Malignant	2 (7%)	
Inguinal, Leukemia Granulocytic		
Inguinal, Lymphoma Malignant	1 (4%)	2 (13%)
Lumbar, Carcinoma, Metastatic, Preputial Gland		
Lumbar, Leukemia Granulocytic		1 (6%)
Lumbar, Lymphoma Malignant	2 (7%)	2 (13%)
Lumbar, Sarcoma, Metastatic, Skin		
Mediastinal, Histiocytic Sarcoma		
Mediastinal, Leukemia Granulocytic		1 (6%)
Mediastinal, Lymphoma Malignant	2 (7%)	3 (19%)
Pancreatic, Leukemia Granulocytic		1 (6%)
Pancreatic, Lymphoma Malignant	2 (7%)	5 (31%)
Popliteal, Lymphoma Malignant	1 (4%)	
Renal, Hemangioma		
Renal, Leukemia Granulocytic		1 (6%)
Renal, Leukemia Mononuclear		
Renal, Lymphoma Malignant	1 (4%)	3 (19%)
Lymph Node, Mandibular	(13)	(15)
Leukemia Granulocytic		1 (7%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (15%)	4 (27%)
Squamous Cell Carcinoma, Metastatic, Skin		
Lymph Node, Mesenteric	(2)	(3)
Leukemia Granulocytic		
Lymphoma Malignant	2 (100%)	3 (100%)
Spleen	(49)	(45)
Hemangiosarcoma		
Histiocytic Sarcoma	1 (2%)	
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Liposarcoma		
Lymphoma Malignant	2 (4%)	5 (11%)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
------------------------------------	------------------	------------------

---

Sarcoma		
Sarcoma, Metastatic, Uncertain Primary Site		
Thymus	(48)	(42)
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	3 (7%)
Mesothelioma Malignant		

---

INTEGUMENTARY SYSTEM

Mammary Gland	(49)	(45)
Adenocarcinoma		
Adenocarcinoma, Multiple		
Adenoma	1 (2%)	
Fibroadenoma	3 (6%)	1 (2%)
Fibroadenoma, Multiple		
Fibroma		1 (2%)
Fibroma, Multiple		
Histiocytic Sarcoma		
Leukemia Granulocytic		
Lipoma		
Lymphoma Malignant	1 (2%)	1 (2%)
Skin	(17)	(16)
Basal Cell Adenoma	1 (6%)	
Basal Cell Carcinoma		
Fibroma		1 (6%)
Keratoacanthoma		
Pilomatrixoma		
Squamous Cell Carcinoma	1 (6%)	
Squamous Cell Papilloma	4 (24%)	1 (6%)
Sebaceous Gland, Adenoma		
Subcutaneous Tissue, Fibroma	3 (18%)	
Subcutaneous Tissue, Fibrosarcoma		
Subcutaneous Tissue, Histiocytic Sarcoma		

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 10034 - 04  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
**CAS Number:** 80-05-7

**Date Report Requested:** 08/16/2017  
**Time Report Requested:** 10:21:03  
**First Dose M/F:** 09/25/12 / 09/25/12  
**Lab:** NCTR

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Subcutaneous Tissue, Histiocytic Sarcoma, Metastatic, Liver		
Subcutaneous Tissue, Lipoma	1 (6%)	1 (6%)
Subcutaneous Tissue, Myxosarcoma		
Subcutaneous Tissue, Sarcoma	1 (6%)	1 (6%)
Subcutaneous Tissue, Schwannoma Malignant		

#### MUSCULOSKELETAL SYSTEM

Bone	(2)	(1)
Cranium, Lymphoma Malignant	1 (50%)	
Cranium, Osteosarcoma		
Mandible, Squamous Cell Carcinoma, Deep Invasion		
Rib, Osteosarcoma		
Tibia, Osteosarcoma		
Vertebra, Chordoma		
Vertebra, Lymphoma Malignant		
Bone, Femur	(50)	(46)
Osteosarcoma		1 (2%)
Skeletal Muscle	(2)	(3)
Lymphoma Malignant		
Mesothelioma Malignant		

#### NERVOUS SYSTEM

Brain, Brain Stem	(50)	(46)
Carcinoma, Deep Invasion		
Granular Cell Tumor Benign		
Granular Cell Tumor Malignant		
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant	1 (2%)	2 (4%)
Brain, Cerebellum	(50)	(46)
Granular Cell Tumor Malignant		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	2 (4%)
Brain, Cerebrum	(50)	(46)
Granular Cell Tumor Benign		
Granular Cell Tumor Malignant		
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	3 (7%)
Meningioma Benign	1 (2%)	
Oligodendroglioma Malignant		1 (2%)
Sarcoma		1 (2%)
Nerve Trigeminal	(8)	(3)
Lymphoma Malignant		1 (33%)
Peripheral Nerve, Sciatic	(8)	(3)
Histiocytic Sarcoma		
Peripheral Nerve, Tibial	(8)	(3)
Histiocytic Sarcoma		
Spinal Cord, Cervical	(8)	(3)
Spinal Cord, Lumbar	(8)	(3)
Lymphoma Malignant		1 (33%)
Spinal Cord, Thoracic	(8)	(3)

---

RESPIRATORY SYSTEM

Lung	(41)	(38)
Alveolar/Bronchiolar Adenoma		
Alveolar/Bronchiolar Carcinoma		
Carcinoma, Metastatic, Zymbal'S Gland		
Chordoma, Metastatic, Bone		
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (3%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (5%)	4 (11%)
Mesothelioma Malignant		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
------------------------------------	------------------	------------------

---

Neural Crest Tumor, Malignant, Metastatic, Ear		
Osteosarcoma, Metastatic, Bone, Femur		1 (3%)
Sarcoma		1 (3%)
Sarcoma, Metastatic, Tissue Nos		1 (3%)
Sarcoma, Metastatic, Uncertain Primary Site		
Nose	(34)	(37)
Adenoma		1 (3%)
Leukemia Granulocytic		1 (3%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (6%)	3 (8%)
Sarcoma, Metastatic, Brain, Cerebrum		1 (3%)
Squamous Cell Carcinoma	1 (3%)	
Trachea	(33)	(33)
Lymphoma Malignant		

---

SPECIAL SENSES SYSTEM

Ear	(0)	(0)
Neural Crest Tumor, Benign		
Neural Crest Tumor, Malignant		
Eye	(1)	(1)
Lymphoma Malignant		
Lacrimal Gland	(0)	(0)
Zymbal's Gland	(0)	(1)
Adenoma		
Carcinoma		

---

URINARY SYSTEM

Kidney	(50)	(45)
Adenoma, Tubular		
Histiocytic Sarcoma		
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lipoma	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
Liposarcoma		
Lymphoma Malignant	2 (4%)	5 (11%)
Mesenchymal Tumor Malignant		
Oncocytoma Benign		
Sarcoma, Metastatic, Spleen		
Urinary Bladder	(3)	(4)
Transitional Epithelium, Carcinoma		
Transitional Epithelium, Papilloma		

---

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(46)
Histiocytic Sarcoma	1 (2%)	
Leukemia Granulocytic		1 (2%)
Leukemia Mononuclear		
Lymphoma Malignant	2 (4%)	5 (11%)
Mesothelioma Malignant		1 (2%)

---

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 Veh. Ctrl M	F1 2.5 BPA M	F1 25.0 BPA M	F1 250.0BPA M	F1 2500.BPA M	F1 25000BPA M
------------------------------------	----------------	--------------	---------------	---------------	---------------	---------------

---

**Tumor Summary for Males**

Total Animals with Primary Neoplasms (b)	39	36	41	40	40	32
Total Primary Neoplasms	62	65	64	66	73	57
Total Animals with Benign Neoplasms	31	29	31	32	28	27
Total Benign Neoplasms	43	47	44	48	48	39
Total Animals with Malignant Neoplasms	16	14	18	15	23	15
Total Malignant Neoplasms	18	18	20	18	25	18
Total Animals with Metastatic Neoplasms		1		2	2	1
Total Metastatic Neoplasms		1		2	14	1
Total Animals with Malignant Neoplasms Uncertain Primary Site					1	
Total Animals with Neoplasms Uncertain- Benign or Malignant	1					
Total Uncertain Neoplasms	1					

---

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 0.05 EE2 M	F1 0.50 EE2 M	F1 Veh. StDose M	F1 2.5 StDose M	F1 25.0 StDose M	F1 250.0StDose M
------------------------------------	---------------	---------------	------------------	-----------------	------------------	------------------

---

**Tumor Summary for Males**

Total Animals with Primary Neoplasms (b)	19	16	41	39	37	38
Total Primary Neoplasms	34	29	77	75	72	61
 Total Animals with Benign Neoplasms	 13	 13	 39	 34	 27	 24
Total Benign Neoplasms	20	21	59	55	49	38
 Total Animals with Malignant Neoplasms	 11	 7	 15	 17	 17	 21
Total Malignant Neoplasms	14	8	18	20	23	23
 Total Animals with Metastatic Neoplasms	 2		 1	 1	 2	 1
Total Metastatic Neoplasms	2		1	2	2	1
 Total Animals with Malignant Neoplasms Uncertain Primary Site						
 Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

---

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Experiment Number: 10034 - 04  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Bisphenol A  
CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
Time Report Requested: 10:21:03  
First Dose M/F: 09/25/12 / 09/25/12  
Lab: NCTR

---

Sprague Dawley (NCTR) RATS MALE	F1 2500.StDose M	F1 25000StDose M
------------------------------------	------------------	------------------

---

### Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	33	35
Total Primary Neoplasms	63	66
Total Animals with Benign Neoplasms	28	25
Total Benign Neoplasms	45	46
Total Animals with Malignant Neoplasms	16	20
Total Malignant Neoplasms	18	20
Total Animals with Metastatic Neoplasms		3
Total Metastatic Neoplasms		4
Total Animals with Malignant Neoplasms Uncertain Primary Site		
Total Animals with Neoplasms Uncertain- Benign or Malignant		
Total Uncertain Neoplasms		

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Primary tumors: all tumors except metastatic tumors



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR)  
RATS FEMALE

F1 Veh. Ctrl F

F1 2.5 BPA F

F1 25.0 BPA F

F1 250.0BPA F

F1 2500.BPA F

F1 25000BPA F

**Disposition Summary**

	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
<b>Animals Initially In Study</b>	<b>50</b>	<b>48</b>	<b>46</b>	<b>49</b>	<b>50</b>	<b>46</b>
<b>Early Deaths</b>						
<b>Moribund Sacrifice</b>	<b>25</b>	<b>22</b>	<b>28</b>	<b>23</b>	<b>28</b>	<b>27</b>
<b>Natural Death</b>	<b>3</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>1</b>
<b>Survivors</b>						
<b>Moribund Sacrifice</b>	<b>3</b>	<b>6</b>	<b>3</b>	<b>8</b>	<b>5</b>	<b>8</b>
<b>Natural Death</b>	<b>3</b>				<b>2</b>	<b>2</b>
<b>Terminal Sacrifice</b>	<b>16</b>	<b>19</b>	<b>14</b>	<b>13</b>	<b>10</b>	<b>8</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>48</b>	<b>46</b>	<b>49</b>	<b>50</b>	<b>46</b>

ALIMENTARY SYSTEM

Esophagus	(34)	(29)	(32)	(36)	(40)	(38)
Intestine Large, Cecum	(1)	(0)	(1)	(0)	(0)	(0)
Lymphoma Malignant	1 (100%)					
Intestine Large, Colon	(31)	(30)	(31)	(32)	(34)	(38)
Adenocarcinoma						
Adenocarcinoma, Metastatic, Uterus						1 (3%)
Lymphoma Malignant	1 (3%)					1 (3%)
Intestine Small, Duodenum	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Small, Ileum	(29)	(29)	(31)	(32)	(32)	(37)
Adenocarcinoma, Metastatic, Uterus						1 (3%)
Leukemia Granulocytic	1 (3%)					
Lymphoma Malignant			1 (3%)			
Intestine Small, Jejunum	(3)	(0)	(2)	(1)	(1)	(0)
Adenocarcinoma			1 (50%)	1 (100%)		
Leiomyoma	1 (33%)					
Leiomyosarcoma	1 (33%)					
Lymphoma Malignant	1 (33%)					
Liver	(50)	(48)	(46)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Fibrosarcoma, Metastatic, Skin						
Hepatocellular Adenoma				1 (2%)	1 (2%)	
Histiocytic Sarcoma						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Histiocytic Sarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)
Sarcoma, Metastatic, Spleen				1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site						
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)		
Mesentery	(2)	(0)	(3)	(3)	(4)	(3)
Adenocarcinoma, Metastatic, Uterus						1 (33%)
Hemangiosarcoma						
Lymphoma Malignant						
Sarcoma, Metastatic, Uncertain Primary Site						
Yolk Sac Carcinoma, Metastatic, Ovary				1 (33%)		
Oral Mucosa	(0)	(0)	(0)	(0)	(0)	(0)
Squamous Cell Papilloma						
Pancreas	(50)	(48)	(46)	(49)	(49)	(46)
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		1 (2%)	
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)		
Acinar Cell, Adenoma						
Stomach, Forestomach	(34)	(29)	(34)	(36)	(39)	(39)
Adenocarcinoma, Metastatic, Uterus						1 (3%)
Lymphoma Malignant						
Squamous Cell Carcinoma						
Squamous Cell Papilloma			1 (3%)			
Stomach, Glandular	(34)	(29)	(31)	(35)	(36)	(38)
Adenocarcinoma, Metastatic, Uterus						1 (3%)
Leukemia Granulocytic	1 (3%)					
Lymphoma Malignant						
Tongue	(0)	(0)	(0)	(0)	(0)	(0)

CARDIOVASCULAR SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Blood Vessel	(50)	(48)	(46)	(49)	(50)	(46)
Lymphoma Malignant						1 (2%)
Heart	(50)	(48)	(46)	(49)	(50)	(46)
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		1 (2%)	1 (2%)
Schwannoma Benign	1 (2%)	1 (2%)				
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site			1 (2%)			
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(50)	(48)	(45)	(49)	(49)	(46)
Adenoma	1 (2%)	1 (2%)		3 (6%)		2 (4%)
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)		1 (2%)		2 (4%)	1 (2%)
Bilateral, Adenoma						
Adrenal Medulla	(50)	(48)	(46)	(49)	(49)	(46)
Lymphoma Malignant					1 (2%)	
Pheochromocytoma Benign		1 (2%)		1 (2%)		2 (4%)
Pheochromocytoma Malignant		1 (2%)			1 (2%)	
Islets, Pancreatic	(50)	(48)	(46)	(49)	(49)	(46)
Adenoma	2 (4%)	1 (2%)			2 (4%)	
Carcinoma			1 (2%)			
Lymphoma Malignant						
Parathyroid Gland	(50)	(48)	(45)	(47)	(50)	(45)
Adenoma			1 (2%)			
Carcinoma, Deep Invasion						
Leukemia Granulocytic	1 (2%)					
Lymphoma Malignant	1 (2%)		1 (2%)			
Pituitary Gland	(50)	(48)	(46)	(49)	(49)	(46)
Leukemia Granulocytic	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Leukemia Mononuclear						
Lymphoma Malignant	1 (2%)		1 (2%)		2 (4%)	1 (2%)
Pars Distalis, Adenoma	21 (42%)	22 (46%)	12 (26%)	20 (41%)	19 (39%)	21 (46%)
Pars Distalis, Carcinoma	1 (2%)	1 (2%)				
Pars Intermedia, Adenoma				1 (2%)		
Thyroid Gland	(50)	(48)	(46)	(49)	(50)	(46)
Leukemia Granulocytic	1 (2%)					
Lymphoma Malignant	1 (2%)		1 (2%)			
C-cell, Adenoma			1 (2%)			2 (4%)
C-cell, Carcinoma		1 (2%)				
Follicular Cell, Carcinoma	1 (2%)					
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(1)	(0)	(1)	(1)	(0)
Fibrosarcoma, Metastatic, Clitoral Gland		1 (100%)				
Fibrosarcoma, Metastatic, Skin						
Leiomyosarcoma					1 (100%)	
Lipoma						
Sarcoma						
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(7)	(7)	(6)	(7)	(8)	(13)
Adenoma						2 (15%)
Carcinoma	1 (14%)	1 (14%)	1 (17%)	1 (14%)	4 (50%)	1 (8%)
Fibrosarcoma		1 (14%)		1 (14%)		
Lymphoma Malignant			1 (17%)			
Squamous Cell Papilloma						
Fat Pad, Ovarian/parametrial	(1)	(0)	(0)	(1)	(1)	(1)
Adenocarcinoma, Metastatic, Uterus						1 (100%)
Ovary	(50)	(48)	(46)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Fibrosarcoma, Metastatic, Skin						
Granulosa Cell Tumor Benign	1 (2%)			1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Granulosa Cell Tumor Malignant	1 (2%)					
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Sex Cord Stromal Tumor, Benign						
Thecoma Benign		1 (2%)				
Thecoma Malignant						
Tubulostromal Adenoma						
Yolk Sac Carcinoma				1 (2%)		
Oviduct	(47)	(48)	(46)	(48)	(47)	(46)
Lymphoma Malignant	1 (2%)		1 (2%)			
Uterus	(50)	(48)	(45)	(49)	(48)	(46)
Histiocytic Sarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	1 (2%)	1 (2%)	1 (2%)			
Polyp Stromal	5 (10%)	3 (6%)	7 (16%)	2 (4%)	4 (8%)	3 (7%)
Polyp Stromal, Multiple						
Sarcoma						
Schwannoma Malignant						
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)		
Cervix, Polyp Stromal						
Cervix, Squamous Cell Carcinoma						
Endometrium, Adenocarcinoma		1 (2%)			1 (2%)	2 (4%)
Endometrium, Adenoma	2 (4%)					
Endothelium, Adenoma						
Vagina	(49)	(48)	(45)	(49)	(50)	(46)
Histiocytic Sarcoma, Metastatic, Skin						
Lymphoma Malignant	1 (2%)		1 (2%)			
Sarcoma Stromal						
Epithelium, Squamous Cell Carcinoma		1 (2%)				

HEMATOPOIETIC SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Bone Marrow	(50)	(48)	(46)	(49)	(49)	(46)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)
Lymph Node	(12)	(9)	(6)	(8)	(4)	(6)
Axillary, Leukemia Granulocytic	1 (8%)					
Axillary, Lymphoma Malignant	1 (8%)				1 (25%)	
Brachial, Lymphoma Malignant						
Cervical, Leukemia Granulocytic	1 (8%)					
Cervical, Lymphoma Malignant	1 (8%)		1 (17%)			
Iliac, Lymphoma Malignant					1 (25%)	
Inguinal, Lymphoma Malignant					1 (25%)	
Lumbar, Leukemia Granulocytic	1 (8%)					
Lumbar, Leukemia Mononuclear						
Lumbar, Lymphoma Malignant	1 (8%)	1 (11%)	1 (17%)			
Mediastinal, Adenocarcinoma, Metastatic, Uterus						1 (17%)
Mediastinal, Fibrosarcoma, Metastatic, Skin						
Mediastinal, Leukemia Granulocytic	1 (8%)					
Mediastinal, Leukemia Mononuclear						
Mediastinal, Lymphoma Malignant	1 (8%)	1 (11%)	1 (17%)			
Pancreatic, Leukemia Granulocytic	1 (8%)					
Pancreatic, Lymphoma Malignant	1 (8%)	1 (11%)	1 (17%)		2 (50%)	
Popliteal, Leukemia Granulocytic	1 (8%)					
Renal, Leukemia Granulocytic	1 (8%)					
Renal, Lymphoma Malignant	1 (8%)	1 (11%)	1 (17%)		2 (50%)	
Lymph Node, Mandibular	(5)	(0)	(4)	(2)	(4)	(6)
Histiocytic Sarcoma						1 (17%)
Leukemia Granulocytic	1 (20%)					
Leukemia Mononuclear						
Lymphoma Malignant	1 (20%)		1 (25%)		1 (25%)	1 (17%)
Lymph Node, Mesenteric	(2)	(1)	(2)	(0)	(0)	(2)
Leukemia Granulocytic	1 (50%)					
Leukemia Mononuclear						
Lymphoma Malignant	1 (50%)	1 (100%)	1 (50%)			1 (50%)
Spleen	(50)	(48)	(46)	(49)	(50)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Fibrosarcoma, Metastatic, Skin						
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)
Sarcoma				1 (2%)		
Thymoma Malignant, Metastatic, Thymus						
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)		
Thymus	(50)	(48)	(44)	(49)	(49)	(45)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)		1 (2%)		1 (2%)	1 (2%)
Squamous Cell Carcinoma						
Thymoma Benign	1 (2%)					
Epithelial Cell, Thymoma Malignant	1 (2%)					
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(50)	(48)	(46)	(49)	(50)	(46)
Adenocarcinoma	2 (4%)	3 (6%)	3 (7%)	3 (6%)	6 (12%)	1 (2%)
Adenocarcinoma, Multiple	2 (4%)	3 (6%)	3 (7%)	2 (4%)	3 (6%)	1 (2%)
Adenoma	2 (4%)	1 (2%)	2 (4%)		2 (4%)	1 (2%)
Adenoma, Multiple				1 (2%)		
Adenosquamous Carcinoma						1 (2%)
Carcinosarcoma	1 (2%)					
Fibroadenoma	20 (40%)	8 (17%)	13 (28%)	7 (14%)	14 (28%)	7 (15%)
Fibroadenoma, Multiple	21 (42%)	32 (67%)	20 (43%)	32 (65%)	21 (42%)	31 (67%)
Fibroma						
Fibrosarcoma, Metastatic, Skin						
Hemangiosarcoma					1 (2%)	
Leukemia Granulocytic	1 (2%)					
Lymphoma Malignant			1 (2%)		2 (4%)	
Mixed Tumor Benign	1 (2%)					
Sarcoma						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Skin	(17)	(12)	(14)	(12)	(13)	(17)
Basal Cell Adenoma	1 (6%)	1 (8%)				
Basal Cell Carcinoma						
Squamous Cell Papilloma	1 (6%)			1 (8%)		1 (6%)
Subcutaneous Tissue, Fibroma						
Subcutaneous Tissue, Fibrosarcoma		1 (8%)			1 (8%)	1 (6%)
Subcutaneous Tissue, Histiocytic Sarcoma						
Subcutaneous Tissue, Lipoma			2 (14%)	1 (8%)		
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(1)	(0)	(0)	(0)	(1)	(0)
Joint, Leukemia Granulocytic	1 (100%)					
Vertebra, Adenocarcinoma, Metastatic, Uterus						
Bone, Femur	(50)	(48)	(46)	(49)	(50)	(46)
Skeletal Muscle	(1)	(1)	(2)	(1)	(1)	(1)
Adenocarcinoma, Metastatic, Uterus						1 (100%)
Lymphoma Malignant						
Rhabdomyosarcoma						
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(50)	(48)	(46)	(49)	(50)	(46)
Carcinoma, Deep Invasion	1 (2%)	1 (2%)				
Glioma Malignant			1 (2%)			
Leukemia Mononuclear						
Lymphoma Malignant						
Oligodendroglioma Malignant		1 (2%)				
Brain, Cerebellum	(50)	(48)	(46)	(49)	(50)	(46)
Glioma Malignant			1 (2%)			
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant						
Brain, Cerebrum	(50)	(48)	(46)	(49)	(50)	(46)
Glioma Malignant			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Granular Cell Tumor Benign						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant			1 (2%)			
Oligodendroglioma Malignant		1 (2%)				
Nerve Trigeminal	(7)	(12)	(2)	(12)	(11)	(6)
Peripheral Nerve, Sciatic	(7)	(12)	(2)	(12)	(11)	(6)
Peripheral Nerve, Tibial	(7)	(12)	(2)	(12)	(11)	(6)
Spinal Cord, Cervical	(7)	(11)	(2)	(12)	(10)	(6)
Spinal Cord, Lumbar	(7)	(12)	(2)	(12)	(10)	(6)
Spinal Cord, Thoracic	(7)	(11)	(2)	(12)	(10)	(6)
<b>RESPIRATORY SYSTEM</b>						
Lung	(38)	(32)	(34)	(39)	(44)	(42)
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Alveolar/Bronchiolar Adenoma			1 (3%)			
Carcinosarcoma, Metastatic, Mammary Gland						
Fibrosarcoma, Metastatic, Skin						
Histiocytic Sarcoma						1 (2%)
Histiocytic Sarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (3%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (5%)	1 (3%)	1 (3%)		1 (2%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Squamous Cell Carcinoma, Metastatic, Thymus						
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site			1 (3%)			
C-cell, Carcinoma, Metastatic, Thyroid Gland		1 (3%)				
Nose	(34)	(29)	(32)	(36)	(38)	(38)
Leukemia Granulocytic	1 (3%)					
Lymphoma Malignant	1 (3%)		1 (3%)		2 (5%)	
Osteosarcoma					1 (3%)	
Trachea	(32)	(29)	(32)	(34)	(37)	(38)
Leukemia Granulocytic	1 (3%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 Veh. Ctrl F	F1 2.5 BPA F	F1 25.0 BPA F	F1 250.0BPA F	F1 2500.BPA F	F1 25000BPA F
Lymphoma Malignant	1 (3%)		1 (3%)			
<b>SPECIAL SENSES SYSTEM</b>						
Ear	(0)	(0)	(0)	(1)	(0)	(0)
Neural Crest Tumor, Benign				1 (100%)		
Eye	(1)	(0)	(1)	(0)	(2)	(0)
Zymbal's Gland	(0)	(1)	(0)	(0)	(2)	(2)
Adenoma					1 (50%)	
Carcinoma		1 (100%)			1 (50%)	2 (100%)
<b>URINARY SYSTEM</b>						
Kidney	(50)	(48)	(46)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus						1 (2%)
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lipoma	1 (2%)					
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site						
Urinary Bladder	(0)	(1)	(0)	(2)	(0)	(1)
<b>SYSTEMIC LESIONS</b>						
Multiple Organ	*(50)	*(48)	*(46)	*(49)	*(50)	*(46)
Histiocytic Sarcoma						1 (2%)
Leukemia Granulocytic	1 (2%)					
Leukemia Mononuclear						
Lymphoma Malignant	2 (4%)	1 (2%)	1 (2%)		2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
--------------------------------------	---------------	---------------	------------------	-----------------	------------------	------------------

**Disposition Summary**

Animals Initially In Study	26	26	50	50	48	50
Early Deaths						
Moribund Sacrifice	17	16	29	29	27	26
Natural Death	1	4	3	4	3	2
Survivors						
Moribund Sacrifice	1	2	7	3	5	9
Natural Death				2		
Terminal Sacrifice	7	4	11	12	13	13
Animals Examined Microscopically	26	26	50	50	48	50

ALIMENTARY SYSTEM

Esophagus	(19)	(22)	(38)	(38)	(35)	(37)
Intestine Large, Cecum	(0)	(0)	(0)	(0)	(0)	(0)
Lymphoma Malignant						
Intestine Large, Colon	(19)	(21)	(38)	(34)	(33)	(35)
Adenocarcinoma						
Adenocarcinoma, Metastatic, Uterus						
Lymphoma Malignant						
Intestine Small, Duodenum	(0)	(1)	(0)	(0)	(0)	(0)
Intestine Small, Ileum	(19)	(18)	(36)	(34)	(31)	(35)
Adenocarcinoma, Metastatic, Uterus						
Leukemia Granulocytic						
Lymphoma Malignant						
Intestine Small, Jejunum	(0)	(2)	(1)	(2)	(0)	(0)
Adenocarcinoma		1 (50%)	1 (100%)	1 (50%)		
Leiomyoma						
Leiomyosarcoma						
Lymphoma Malignant						
Liver	(26)	(26)	(49)	(50)	(48)	(50)
Adenocarcinoma, Metastatic, Uterus						
Fibrosarcoma, Metastatic, Skin						
Hepatocellular Adenoma		1 (4%)				
Histiocytic Sarcoma						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Histiocytic Sarcoma, Metastatic, Skin				1 (2%)		
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		1 (2%)
Sarcoma, Metastatic, Spleen						
Sarcoma, Metastatic, Uncertain Primary Site	1 (4%)					
Yolk Sac Carcinoma, Metastatic, Ovary						
Mesentery	(2)	(1)	(2)	(3)	(1)	(2)
Adenocarcinoma, Metastatic, Uterus						
Hemangiosarcoma					1 (100%)	
Lymphoma Malignant				1 (33%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (50%)					
Yolk Sac Carcinoma, Metastatic, Ovary						
Oral Mucosa	(0)	(0)	(1)	(0)	(1)	(0)
Squamous Cell Papilloma			1 (100%)		1 (100%)	
Pancreas	(26)	(26)	(49)	(49)	(47)	(49)
Adenocarcinoma, Metastatic, Uterus						
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		
Yolk Sac Carcinoma, Metastatic, Ovary						
Acinar Cell, Adenoma						
Stomach, Forestomach	(19)	(22)	(38)	(38)	(35)	(37)
Adenocarcinoma, Metastatic, Uterus						
Lymphoma Malignant						
Squamous Cell Carcinoma						
Squamous Cell Papilloma						
Stomach, Glandular	(19)	(21)	(38)	(36)	(33)	(37)
Adenocarcinoma, Metastatic, Uterus						
Leukemia Granulocytic						
Lymphoma Malignant						
Tongue	(0)	(1)	(0)	(0)	(0)	(0)

CARDIOVASCULAR SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Blood Vessel	(26)	(26)	(50)	(50)	(48)	(50)
Lymphoma Malignant						
Heart	(26)	(26)	(50)	(50)	(48)	(50)
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		
Schwannoma Benign			2 (4%)			
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site						
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(26)	(26)	(49)	(49)	(48)	(50)
Adenoma		1 (4%)				1 (2%)
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Bilateral, Adenoma						1 (2%)
Adrenal Medulla	(26)	(26)	(49)	(50)	(48)	(48)
Lymphoma Malignant				1 (2%)		
Pheochromocytoma Benign	1 (4%)	2 (8%)	2 (4%)		1 (2%)	1 (2%)
Pheochromocytoma Malignant						
Islets, Pancreatic	(26)	(26)	(49)	(50)	(48)	(49)
Adenoma	1 (4%)			1 (2%)	1 (2%)	1 (2%)
Carcinoma						
Lymphoma Malignant						
Parathyroid Gland	(26)	(26)	(45)	(49)	(47)	(47)
Adenoma						
Carcinoma, Deep Invasion						1 (2%)
Leukemia Granulocytic						
Lymphoma Malignant						
Pituitary Gland	(26)	(26)	(49)	(50)	(48)	(50)
Leukemia Granulocytic						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A  
CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Pars Distalis, Adenoma	10 (38%)	17 (65%)	23 (47%)	16 (32%)	14 (29%)	20 (40%)
Pars Distalis, Carcinoma		3 (12%)				1 (2%)
Pars Intermedia, Adenoma						
Thyroid Gland	(26)	(25)	(48)	(49)	(45)	(48)
Leukemia Granulocytic						
Lymphoma Malignant				1 (2%)		
C-cell, Adenoma		2 (8%)		1 (2%)		
C-cell, Carcinoma						2 (4%)
Follicular Cell, Carcinoma						
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(2)	(0)	(1)	(0)	(0)	(0)
Fibrosarcoma, Metastatic, Clitoral Gland						
Fibrosarcoma, Metastatic, Skin	1 (50%)					
Leiomyosarcoma						
Lipoma			1 (100%)			
Sarcoma	1 (50%)					
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(2)	(6)	(6)	(6)	(6)	(8)
Adenoma		2 (33%)	1 (17%)			1 (13%)
Carcinoma			1 (17%)			1 (13%)
Fibrosarcoma						
Lymphoma Malignant						
Squamous Cell Papilloma						1 (13%)
Fat Pad, Ovarian/parametrial	(0)	(0)	(0)	(0)	(0)	(0)
Adenocarcinoma, Metastatic, Uterus						
Ovary	(26)	(26)	(49)	(49)	(47)	(50)
Adenocarcinoma, Metastatic, Uterus						
Fibrosarcoma, Metastatic, Skin						
Granulosa Cell Tumor Benign			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Granulosa Cell Tumor Malignant						
Leukemia Granulocytic						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (4%)					
Sex Cord Stromal Tumor, Benign					1 (2%)	
Thecoma Benign						
Thecoma Malignant						
Tubulostromal Adenoma	1 (4%)					
Yolk Sac Carcinoma						
Oviduct	(26)	(26)	(49)	(49)	(45)	(48)
Lymphoma Malignant				1 (2%)		
Uterus	(26)	(26)	(49)	(49)	(48)	(49)
Histiocytic Sarcoma, Metastatic, Skin				1 (2%)		
Leukemia Granulocytic						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Polyp Stromal	3 (12%)	1 (4%)	7 (14%)	4 (8%)	5 (10%)	5 (10%)
Polyp Stromal, Multiple						1 (2%)
Sarcoma					1 (2%)	
Schwannoma Malignant					1 (2%)	
Yolk Sac Carcinoma, Metastatic, Ovary						
Cervix, Polyp Stromal						1 (2%)
Cervix, Squamous Cell Carcinoma		1 (4%)				
Endometrium, Adenocarcinoma			1 (2%)	1 (2%)		
Endometrium, Adenoma						
Endothelium, Adenoma				1 (2%)		
Vagina	(26)	(26)	(49)	(50)	(47)	(49)
Histiocytic Sarcoma, Metastatic, Skin				1 (2%)		
Lymphoma Malignant						
Sarcoma Stromal						
Epithelium, Squamous Cell Carcinoma						

HEMATOPOIETIC SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Bone Marrow	(26)	(26)	(49)	(49)	(47)	(49)
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		1 (2%)
Lymph Node	(4)	(3)	(9)	(6)	(3)	(10)
Axillary, Leukemia Granulocytic						
Axillary, Lymphoma Malignant				1 (17%)		
Brachial, Lymphoma Malignant				1 (17%)		
Cervical, Leukemia Granulocytic						
Cervical, Lymphoma Malignant				1 (17%)		
Iliac, Lymphoma Malignant						
Inguinal, Lymphoma Malignant						
Lumbar, Leukemia Granulocytic						
Lumbar, Leukemia Mononuclear						1 (10%)
Lumbar, Lymphoma Malignant				1 (17%)		
Mediastinal, Adenocarcinoma, Metastatic, Uterus						
Mediastinal, Fibrosarcoma, Metastatic, Skin						
Mediastinal, Leukemia Granulocytic						
Mediastinal, Leukemia Mononuclear						1 (10%)
Mediastinal, Lymphoma Malignant				1 (17%)		
Pancreatic, Leukemia Granulocytic						
Pancreatic, Lymphoma Malignant				1 (17%)		
Popliteal, Leukemia Granulocytic						
Renal, Leukemia Granulocytic						
Renal, Lymphoma Malignant				1 (17%)		
Lymph Node, Mandibular	(0)	(1)	(4)	(5)	(3)	(8)
Histiocytic Sarcoma						
Leukemia Granulocytic						
Leukemia Mononuclear						1 (13%)
Lymphoma Malignant				1 (20%)		
Lymph Node, Mesenteric	(1)	(0)	(0)	(1)	(0)	(1)
Leukemia Granulocytic						
Leukemia Mononuclear						1 (100%)
Lymphoma Malignant				1 (100%)		
Spleen	(26)	(26)	(49)	(50)	(47)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Adenocarcinoma, Metastatic, Uterus						
Fibrosarcoma, Metastatic, Skin						
Histiocytic Sarcoma						
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		1 (2%)
Sarcoma						1 (2%)
Thymoma Malignant, Metastatic, Thymus		1 (4%)				
Yolk Sac Carcinoma, Metastatic, Ovary						
Thymus	(26)	(26)	(49)	(50)	(48)	(50)
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		1 (2%)
Squamous Cell Carcinoma				1 (2%)		
Thymoma Benign			1 (2%)			
Epithelial Cell, Thymoma Malignant		1 (4%)				

INTEGUMENTARY SYSTEM

Mammary Gland	(26)	(26)	(50)	(50)	(48)	(49)
Adenocarcinoma	2 (8%)	6 (23%)	2 (4%)	10 (20%)	4 (8%)	5 (10%)
Adenocarcinoma, Multiple		4 (15%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Adenoma			1 (2%)	1 (2%)		3 (6%)
Adenoma, Multiple						
Adenosquamous Carcinoma						
Carcinosarcoma					2 (4%)	
Fibroadenoma	7 (27%)	10 (38%)	14 (28%)	13 (26%)	9 (19%)	11 (22%)
Fibroadenoma, Multiple	11 (42%)	4 (15%)	29 (58%)	32 (64%)	28 (58%)	31 (63%)
Fibroma			1 (2%)			
Fibrosarcoma, Metastatic, Skin						
Hemangiosarcoma						
Leukemia Granulocytic						
Lymphoma Malignant						
Mixed Tumor Benign						
Sarcoma	1 (4%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Skin	(9)	(9)	(16)	(8)	(8)	(19)
Basal Cell Adenoma			2 (13%)		1 (13%)	1 (5%)
Basal Cell Carcinoma						
Squamous Cell Papilloma			1 (6%)			2 (11%)
Subcutaneous Tissue, Fibroma						1 (5%)
Subcutaneous Tissue, Fibrosarcoma	1 (11%)			1 (13%)	2 (25%)	
Subcutaneous Tissue, Histiocytic Sarcoma				2 (25%)		
Subcutaneous Tissue, Lipoma			1 (6%)			1 (5%)
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(0)	(2)	(0)	(0)	(0)
Joint, Leukemia Granulocytic						
Vertebra, Adenocarcinoma, Metastatic, Uterus			1 (50%)			
Bone, Femur	(26)	(26)	(50)	(50)	(48)	(50)
Skeletal Muscle	(0)	(3)	(0)	(0)	(0)	(1)
Adenocarcinoma, Metastatic, Uterus						
Lymphoma Malignant						
Rhabdomyosarcoma		1 (33%)				
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(26)	(26)	(49)	(50)	(48)	(50)
Carcinoma, Deep Invasion		3 (12%)				
Glioma Malignant						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Oligodendroglioma Malignant						
Brain, Cerebellum	(26)	(26)	(49)	(50)	(48)	(50)
Glioma Malignant						
Leukemia Granulocytic						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Brain, Cerebrum	(26)	(26)	(49)	(50)	(48)	(50)
Glioma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Granular Cell Tumor Benign		1 (4%)				
Leukemia Granulocytic						
Leukemia Mononuclear						1 (2%)
Lymphoma Malignant				1 (2%)		
Oligodendroglioma Malignant						
Nerve Trigeminal	(5)	(4)	(1)	(3)	(0)	(3)
Peripheral Nerve, Sciatic	(5)	(4)	(1)	(3)	(0)	(3)
Peripheral Nerve, Tibial	(5)	(4)	(1)	(3)	(0)	(3)
Spinal Cord, Cervical	(5)	(4)	(1)	(3)	(0)	(3)
Spinal Cord, Lumbar	(5)	(4)	(1)	(3)	(0)	(3)
Spinal Cord, Thoracic	(5)	(4)	(1)	(3)	(0)	(3)

RESPIRATORY SYSTEM

Lung	(21)	(22)	(40)	(40)	(39)	(40)
Adenocarcinoma, Metastatic, Uterus			1 (3%)			
Alveolar/Bronchiolar Adenoma						
Carcinosarcoma, Metastatic, Mammary Gland					1 (3%)	
Fibrosarcoma, Metastatic, Skin						
Histiocytic Sarcoma						
Histiocytic Sarcoma, Metastatic, Skin				1 (3%)		
Leukemia Granulocytic						
Leukemia Mononuclear						1 (3%)
Lymphoma Malignant				1 (3%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (5%)					
Squamous Cell Carcinoma, Metastatic, Thymus				1 (3%)		
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site						
C-cell, Carcinoma, Metastatic, Thyroid Gland						
Nose	(19)	(22)	(38)	(36)	(35)	(37)
Leukemia Granulocytic						
Lymphoma Malignant				1 (3%)		
Osteosarcoma						
Trachea	(19)	(20)	(38)	(36)	(33)	(35)
Leukemia Granulocytic						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
Lymphoma Malignant						
<b>SPECIAL SENSES SYSTEM</b>						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Neural Crest Tumor, Benign						
Eye	(0)	(0)	(0)	(0)	(0)	(0)
Zymbal's Gland	(1)	(0)	(0)	(1)	(0)	(0)
Adenoma				1 (100%)		
Carcinoma						
<b>URINARY SYSTEM</b>						
Kidney	(26)	(26)	(49)	(50)	(47)	(49)
Adenocarcinoma, Metastatic, Uterus						
Fibrosarcoma, Metastatic, Skin						
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lipoma						
Lymphoma Malignant				1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (4%)					
Urinary Bladder	(1)	(0)	(0)	(1)	(0)	(0)
<b>SYSTEMIC LESIONS</b>						
Multiple Organ	*(26)	*(26)	*(50)	*(50)	*(48)	*(50)
Histiocytic Sarcoma				2 (4%)		
Leukemia Granulocytic						
Leukemia Mononuclear						2 (4%)
Lymphoma Malignant				1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
--------------------------------------	------------------	------------------

## Disposition Summary

Animals Initially In Study	50	46
Early Deaths		
Moribund Sacrifice	26	25
Natural Death	3	2
Survivors		
Moribund Sacrifice	4	6
Natural Death		
Terminal Sacrifice	17	13
Animals Examined Microscopically	50	46

## ALIMENTARY SYSTEM

Esophagus	(33)	(33)
Intestine Large, Cecum	(0)	(0)
Lymphoma Malignant		
Intestine Large, Colon	(32)	(33)
Adenocarcinoma		1 (3%)
Adenocarcinoma, Metastatic, Uterus		
Lymphoma Malignant		
Intestine Small, Duodenum	(0)	(0)
Intestine Small, Ileum	(30)	(33)
Adenocarcinoma, Metastatic, Uterus		
Leukemia Granulocytic		
Lymphoma Malignant		1 (3%)
Intestine Small, Jejunum	(0)	(0)
Adenocarcinoma		
Leiomyoma		
Leiomyosarcoma		
Lymphoma Malignant		
Liver	(50)	(46)
Adenocarcinoma, Metastatic, Uterus		
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Hepatocellular Adenoma		1 (2%)
Histiocytic Sarcoma	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Histiocytic Sarcoma, Metastatic, Skin		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Sarcoma, Metastatic, Spleen		
Sarcoma, Metastatic, Uncertain Primary Site		
Yolk Sac Carcinoma, Metastatic, Ovary		
Mesentery	(1)	(3)
Adenocarcinoma, Metastatic, Uterus		
Hemangiosarcoma		
Lymphoma Malignant		
Sarcoma, Metastatic, Uncertain Primary Site		
Yolk Sac Carcinoma, Metastatic, Ovary		
Oral Mucosa	(0)	(1)
Squamous Cell Papilloma		1 (100%)
Pancreas	(49)	(46)
Adenocarcinoma, Metastatic, Uterus		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Yolk Sac Carcinoma, Metastatic, Ovary		
Acinar Cell, Adenoma	1 (2%)	
Stomach, Forestomach	(34)	(34)
Adenocarcinoma, Metastatic, Uterus		
Lymphoma Malignant		2 (6%)
Squamous Cell Carcinoma	1 (3%)	
Squamous Cell Papilloma		1 (3%)
Stomach, Glandular	(32)	(32)
Adenocarcinoma, Metastatic, Uterus		
Leukemia Granulocytic		
Lymphoma Malignant		1 (3%)
Tongue	(0)	(0)

---

CARDIOVASCULAR SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Blood Vessel	(50)	(46)
Lymphoma Malignant		1 (2%)
Heart	(50)	(46)
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Schwannoma Benign		
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site		

---

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(46)
Adenoma		1 (2%)
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Bilateral, Adenoma		
Adrenal Medulla	(50)	(45)
Lymphoma Malignant		1 (2%)
Pheochromocytoma Benign		1 (2%)
Pheochromocytoma Malignant		
Islets, Pancreatic	(49)	(46)
Adenoma	1 (2%)	1 (2%)
Carcinoma	1 (2%)	
Lymphoma Malignant		1 (2%)
Parathyroid Gland	(47)	(46)
Adenoma	1 (2%)	
Carcinoma, Deep Invasion		
Leukemia Granulocytic		
Lymphoma Malignant		1 (2%)
Pituitary Gland	(50)	(46)
Leukemia Granulocytic		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Pars Distalis, Adenoma	20 (40%)	20 (43%)
Pars Distalis, Carcinoma		1 (2%)
Pars Intermedia, Adenoma		
Thyroid Gland	(50)	(46)
Leukemia Granulocytic		
Lymphoma Malignant		1 (2%)
C-cell, Adenoma		
C-cell, Carcinoma		
Follicular Cell, Carcinoma		

---

GENERAL BODY SYSTEM

Tissue NOS	(0)	(1)
Fibrosarcoma, Metastatic, Clitoral Gland		
Fibrosarcoma, Metastatic, Skin		
Leiomyosarcoma		
Lipoma		1 (100%)
Sarcoma		

---

GENITAL SYSTEM

Clitoral Gland	(6)	(7)
Adenoma		1 (14%)
Carcinoma	2 (33%)	1 (14%)
Fibrosarcoma		
Lymphoma Malignant		
Squamous Cell Papilloma		
Fat Pad, Ovarian/parametrial	(1)	(0)
Adenocarcinoma, Metastatic, Uterus		
Ovary	(50)	(46)
Adenocarcinoma, Metastatic, Uterus		
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Granulosa Cell Tumor Benign		

---

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Granulosa Cell Tumor Malignant		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site		
Sex Cord Stromal Tumor, Benign		
Thecoma Benign		
Thecoma Malignant	1 (2%)	
Tubulostromal Adenoma		
Yolk Sac Carcinoma		
Oviduct	(49)	(46)
Lymphoma Malignant		2 (4%)
Uterus	(49)	(46)
Histiocytic Sarcoma, Metastatic, Skin		
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant		2 (4%)
Polyp Stromal	4 (8%)	1 (2%)
Polyp Stromal, Multiple		
Sarcoma		
Schwannoma Malignant		
Yolk Sac Carcinoma, Metastatic, Ovary		
Cervix, Polyp Stromal		
Cervix, Squamous Cell Carcinoma		
Endometrium, Adenocarcinoma		
Endometrium, Adenoma		1 (2%)
Endothelium, Adenoma		
Vagina	(49)	(46)
Histiocytic Sarcoma, Metastatic, Skin		
Lymphoma Malignant		1 (2%)
Sarcoma Stromal	1 (2%)	
Epithelium, Squamous Cell Carcinoma		

---

HEMATOPOIETIC SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Bone Marrow	(49)	(45)
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		1 (2%)
Lymph Node	(4)	(11)
Axillary, Leukemia Granulocytic		
Axillary, Lymphoma Malignant		2 (18%)
Brachial, Lymphoma Malignant		
Cervical, Leukemia Granulocytic		
Cervical, Lymphoma Malignant		2 (18%)
Iliac, Lymphoma Malignant		
Inguinal, Lymphoma Malignant		1 (9%)
Lumbar, Leukemia Granulocytic		
Lumbar, Leukemia Mononuclear		
Lumbar, Lymphoma Malignant		2 (18%)
Mediastinal, Adenocarcinoma, Metastatic, Uterus		
Mediastinal, Fibrosarcoma, Metastatic, Skin	1 (25%)	
Mediastinal, Leukemia Granulocytic		
Mediastinal, Leukemia Mononuclear		
Mediastinal, Lymphoma Malignant		1 (9%)
Pancreatic, Leukemia Granulocytic		
Pancreatic, Lymphoma Malignant		2 (18%)
Popliteal, Leukemia Granulocytic		
Renal, Leukemia Granulocytic		
Renal, Lymphoma Malignant		2 (18%)
Lymph Node, Mandibular	(6)	(5)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant		2 (40%)
Lymph Node, Mesenteric	(0)	(2)
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant		2 (100%)
Spleen	(49)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Adenocarcinoma, Metastatic, Uterus		
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Histiocytic Sarcoma		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Sarcoma		
Thymoma Malignant, Metastatic, Thymus		
Yolk Sac Carcinoma, Metastatic, Ovary		
Thymus	(49)	(46)
Leukemia Granulocytic		
Leukemia Mononuclear		
Lymphoma Malignant	1 (2%)	2 (4%)
Squamous Cell Carcinoma		
Thymoma Benign		1 (2%)
Epithelial Cell, Thymoma Malignant		

---

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(46)
Adenocarcinoma	8 (16%)	3 (7%)
Adenocarcinoma, Multiple	1 (2%)	2 (4%)
Adenoma		1 (2%)
Adenoma, Multiple		
Adenosquamous Carcinoma	1 (2%)	
Carcinosarcoma		
Fibroadenoma	7 (14%)	6 (13%)
Fibroadenoma, Multiple	29 (58%)	28 (61%)
Fibroma		
Fibrosarcoma, Metastatic, Skin	1 (2%)	
Hemangiosarcoma		
Leukemia Granulocytic		
Lymphoma Malignant		2 (4%)
Mixed Tumor Benign		
Sarcoma		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Skin	(16)	(12)
Basal Cell Adenoma	1 (6%)	
Basal Cell Carcinoma		1 (8%)
Squamous Cell Papilloma		
Subcutaneous Tissue, Fibroma	1 (6%)	
Subcutaneous Tissue, Fibrosarcoma	2 (13%)	
Subcutaneous Tissue, Histiocytic Sarcoma		
Subcutaneous Tissue, Lipoma	1 (6%)	1 (8%)

---

MUSCULOSKELETAL SYSTEM

Bone	(0)	(0)
Joint, Leukemia Granulocytic		
Vertebra, Adenocarcinoma, Metastatic, Uterus		
Bone, Femur	(50)	(46)
Skeletal Muscle	(0)	(2)
Adenocarcinoma, Metastatic, Uterus		
Lymphoma Malignant		1 (50%)
Rhabdomyosarcoma		

---

NERVOUS SYSTEM

Brain, Brain Stem	(50)	(46)
Carcinoma, Deep Invasion		1 (2%)
Glioma Malignant		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Oligodendroglioma Malignant		
Brain, Cerebellum	(50)	(46)
Glioma Malignant		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Brain, Cerebrum	(50)	(46)
Glioma Malignant	1 (2%)	1 (2%)

---

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
Granular Cell Tumor Benign		1 (2%)
Leukemia Granulocytic		
Leukemia Mononuclear	1 (2%)	
Lymphoma Malignant		2 (4%)
Oligodendroglioma Malignant		
Nerve Trigeminal	(3)	(4)
Peripheral Nerve, Sciatic	(3)	(4)
Peripheral Nerve, Tibial	(3)	(4)
Spinal Cord, Cervical	(3)	(4)
Spinal Cord, Lumbar	(3)	(4)
Spinal Cord, Thoracic	(3)	(4)

---

RESPIRATORY SYSTEM

Lung	(39)	(37)
Adenocarcinoma, Metastatic, Uterus		
Alveolar/Bronchiolar Adenoma		
Carcinosarcoma, Metastatic, Mammary Gland		
Fibrosarcoma, Metastatic, Skin	1 (3%)	
Histiocytic Sarcoma		
Histiocytic Sarcoma, Metastatic, Skin		
Leukemia Granulocytic		
Leukemia Mononuclear	1 (3%)	
Lymphoma Malignant		2 (5%)
Sarcoma, Metastatic, Uncertain Primary Site		
Squamous Cell Carcinoma, Metastatic, Thymus		
Yolk Sac Carcinoma, Metastatic, Uncertain Primary Site		
C-cell, Carcinoma, Metastatic, Thyroid Gland		
Nose	(32)	(33)
Leukemia Granulocytic		
Lymphoma Malignant		2 (6%)
Osteosarcoma		
Trachea	(32)	(33)
Leukemia Granulocytic		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10034 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Bisphenol A

CAS Number: 80-05-7

Date Report Requested: 08/16/2017

Time Report Requested: 10:21:03

First Dose M/F: 09/25/12 / 09/25/12

Lab: NCTR

---

Sprague Dawley (NCTR)  
RATS FEMALE

F1 2500.StDose F

F1 25000StDose F

---

Lymphoma Malignant

1 (3%)

---

SPECIAL SENSES SYSTEM

Ear

(0)

(1)

Neural Crest Tumor, Benign

1 (100%)

Eye

(1)

(0)

Zymbal's Gland

(0)

(0)

Adenoma

Carcinoma

---

URINARY SYSTEM

Kidney

(50)

(46)

Adenocarcinoma, Metastatic, Uterus

Fibrosarcoma, Metastatic, Skin

1 (2%)

Leukemia Granulocytic

Leukemia Mononuclear

1 (2%)

Lipoma

2 (4%)

Lymphoma Malignant

2 (4%)

Sarcoma, Metastatic, Uncertain Primary Site

Urinary Bladder

(1)

(1)

---

SYSTEMIC LESIONS

Multiple Organ

\*(50)

\*(46)

Histiocytic Sarcoma

1 (2%)

Leukemia Granulocytic

Leukemia Mononuclear

1 (2%)

Lymphoma Malignant

1 (2%)

2 (4%)

---

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

Sprague Dawley (NCTR)  
 RATS FEMALE

F1 Veh. Ctrl F

F1 2.5 BPA F

F1 25.0 BPA F

F1 250.0BPA F

F1 2500.BPA F

F1 25000BPA F

**Tumor Summary for Females**

Total Animals with Primary Neoplasms (b)	47	44	38	47	45	43
Total Primary Neoplasms	97	91	73	83	86	83
Total Animals with Benign Neoplasms	44	43	37	44	40	41
Total Benign Neoplasms	82	72	60	71	64	72
Total Animals with Malignant Neoplasms	13	17	11	12	19	11
Total Malignant Neoplasms	15	19	13	12	22	11
Total Animals with Metastatic Neoplasms		2	1	2		1
Total Metastatic Neoplasms		2	2	6		14
Total Animals with Malignant Neoplasms Uncertain Primary Site			1			
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Experiment Number: 10034 - 04  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: RATS/Sprague Dawley (NCTR)

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
 Bisphenol A  
 CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
 Time Report Requested: 10:21:03  
 First Dose M/F: 09/25/12 / 09/25/12  
 Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 0.05 EE2 F	F1 0.50 EE2 F	F1 Veh. StDose F	F1 2.5 StDose F	F1 25.0 StDose F	F1 250.0StDose F
--------------------------------------	---------------	---------------	------------------	-----------------	------------------	------------------

---

**Tumor Summary for Females**

Total Animals with Primary Neoplasms (b)	22	25	49	49	46	48
Total Primary Neoplasms	39	61	94	89	73	99
 Total Animals with Benign Neoplasms	 21	 24	 48	 47	 44	 46
Total Benign Neoplasms	34	41	88	71	61	83
 Total Animals with Malignant Neoplasms	 4	 12	 6	 16	 12	 15
Total Malignant Neoplasms	5	20	6	18	12	16
 Total Animals with Metastatic Neoplasms	 2	 1	 1	 3	 1	 1
Total Metastatic Neoplasms	6	1	2	5	1	1
 Total Animals with Malignant Neoplasms Uncertain Primary Site	 1					
 Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

---

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors



Experiment Number: 10034 - 04  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: RATS/Sprague Dawley (NCTR)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Bisphenol A  
CAS Number: 80-05-7

Date Report Requested: 08/16/2017  
Time Report Requested: 10:21:03  
First Dose M/F: 09/25/12 / 09/25/12  
Lab: NCTR

---

Sprague Dawley (NCTR) RATS FEMALE	F1 2500.StDose F	F1 25000StDose F
--------------------------------------	------------------	------------------

---

### Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	46	46
Total Primary Neoplasms	90	82
Total Animals with Benign Neoplasms	45	43
Total Benign Neoplasms	68	68
Total Animals with Malignant Neoplasms	15	13
Total Malignant Neoplasms	22	14
Total Animals with Metastatic Neoplasms	1	
Total Metastatic Neoplasms	9	
Total Animals with Malignant Neoplasms Uncertain Primary Site		
Total Animals with Neoplasms Uncertain- Benign or Malignant		
Total Uncertain Neoplasms		

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Primary tumors: all tumors except metastatic tumors